Original Article
Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus
N Engl J Med 2009; 361:1945-1952November 12, 2009
- Abstract
Background
A new pandemic influenza A (H1N1) virus has emerged, causing illness globally, primarily in younger age groups. To assess the level of preexisting immunity in humans and to evaluate seasonal vaccine strategies, we measured the antibody response to the pandemic virus resulting from previous influenza infection or vaccination in different age groups.
Methods
Using a microneutralization assay, we measured cross-reactive antibodies to pandemic H1N1 virus (2009 H1N1) in stored serum samples from persons who either donated blood or were vaccinated with recent seasonal or 1976 swine influenza vaccines.
Results
A total of 4 of 107 persons (4%) who were born after 1980 had preexisting cross-reactive antibody titers of 40 or more against 2009 H1N1, whereas 39 of 115 persons (34%) born before 1950 had titers of 80 or more. Vaccination with seasonal trivalent inactivated influenza vaccines resulted in an increase in the level of cross-reactive antibody to 2009 H1N1 by a factor of four or more in none of 55 children between the ages of 6 months and 9 years, in 12 to 22% of 231 adults between the ages of 18 and 64 years, and in 5% or less of 113 adults 60 years of age or older. Seasonal vaccines that were formulated with adjuvant did not further enhance cross-reactive antibody responses. Vaccination with the A/New Jersey/1976 swine influenza vaccine substantially boosted cross-reactive antibodies to 2009 H1N1 in adults.
Conclusions
Vaccination with recent seasonal nonadjuvanted or adjuvanted influenza vaccines induced little or no cross-reactive antibody response to 2009 H1N1 in any age group. Persons under the age of 30 years had little evidence of cross-reactive antibodies to the pandemic virus. However, a proportion of older adults had preexisting cross-reactive antibodies.
Media in This Article
Figure 1
Neutralizing Antibody Titers against the 2009 Pandemic H1N1 Virus among Serum Donors, According to Birth Decade (1880–2000).Table 1
Cross-Reactive Microneutralization Antibody Response against Pandemic Influenza A (H1N1) Virus in Pediatric and Adult Recipients of Seasonal Trivalent Inactivated Influenza Vaccines.Article Activity
- Article
On June 11, 2009, the World Health Organization declared that an influenza pandemic was under way. The 2009 pandemic H1N1 virus (2009 H1N1) has a unique combination of genes from both North American and Eurasian swine lineages that has not been identified previously in either swine or human populations.1,2 The hemagglutinin gene of 2009 H1N1 belongs to the classical swine lineage, which was first introduced into swine populations around 1918 and shares antigenic similarity with triple reassortant swine influenza viruses that have circulated in pigs in the United States for more than a decade; these strains have been associated with sporadic human disease.2-4 The 2009 H1N1 hemagglutinin is antigenically and genetically distinct from hemagglutinins of contemporary human seasonal influenza H1N1 viruses but has greater similarity to the swine H1N1 influenza virus that caused an influenza outbreak among military recruits in Fort Dix, New Jersey, in 1976.2,5 This outbreak led to a national vaccination campaign in which approximately 45 million people were vaccinated.6
Little is known about the level of preexisting immunity to 2009 H1N1 in humans, one of the determining factors for susceptibility to a novel influenza virus. Our preliminary studies suggested that children under the age of 10 years may have little or no preexisting immunity but that adults over the age of 60 years may have some level of cross-reactive antibody to the pandemic strain.7 To inform a public health response to the pandemic, we further assessed the extent of cross-reactive antibodies against 2009 H1N1 that were present in pediatric, adult, and older adult populations as a result of previous influenza infection or recent vaccination with seasonal nonadjuvanted or adjuvanted vaccines. To better define the age distribution and possible origin for cross-reactive antibody against 2009 H1N1, we also evaluated serum samples from the general population, spanning birth decades during the past 130 years, as well as a cohort of subjects who received the 1976 swine influenza vaccine.
Methods
Study Design
We collected stored-serum panels from vaccine trials conducted in 1976 or between 2005 and 2009 from academic, government, and industry partners. Serum samples were collected with approval from the institutional review board at each contributing institution, and written informed consent was provided. The testing of serum samples at the Centers for Disease Control and Prevention (CDC) was considered to be a public health, nonresearch activity that was exempt from human-subjects review. Details of the vaccine study cohorts and the vaccine products that were used are provided in the figure in the Supplementary Appendix, available with the full text of this article at NEJM.org. In addition, we also tested 417 serum samples that were collected anonymously in the United States, consisting of 59 samples that were collected in 19718 and 358 samples that were collected from July 2002 through February 2009 (for details, see the Methods section in the Supplementary Appendix).
Using a microneutralization assay and a hemagglutination-inhibition assay with 0.5% turkey erythrocytes for a subgroup of serum samples,9,10 we tested the samples for antibody responses to 2009 H1N1, A/California/04/2009, seasonal H1N1 viruses, and A/New Jersey/8/1976 (A/NJ/76) virus (for details about the assays and the hemagglutination-inhibition assay results, see the Methods section and Table 1 in the Supplementary Appendix). Because the microneutralization assay correlated well with the hemagglutination-inhibition assay (r=0.7) but generally yielded higher titers and more seroconversions among vaccinated subjects, the microneutralization assay was the primary serologic test used. The seasonal influenza A H1N1 viruses and the swine influenza A/NJ/76 virus were propagated in embryonated chicken eggs. A/California/04/2009 was propagated in Madin–Darby canine kidney (MDCK) cells, as detailed in the Supplementary Appendix.
Statistical Analysis
To estimate the value of the microneutralization titer corresponding to a hemagglutination titer of 40 (a measure that has been associated with at least a 50% reduction in the risk of infection or disease with influenza viruses in human populations), we performed a correlation analysis using linear regression models.11-13 Analyses were performed to fit linear regression and multivariable models, to perform t-tests, and to estimate geometric mean titers (GMTs) with confidence intervals and corresponding P values with the use of SAS software (version 9.1). For analysis of the data for the 417 serum samples, we evaluated titers on the basis of the birth decade of the serum donor and computed the cumulative GMT by averaging the mean log microneutralization titers for that specific decade and preceding decades, giving each decade equal weight regardless of varying sample sizes. A P value of less than 0.05 was considered to indicate statistical significance. (For details regarding the statistical analysis, see the Supplementary Appendix.)
Results
Cross-Reactive Antibodies before and after Seasonal Influenza Vaccination
We detected little or no preexisting cross-reactive antibody against 2009 H1N1 in 124 samples from children ranging in age from 6 months to 9 years (Table 1Table 1
Cross-Reactive Microneutralization Antibody Response against Pandemic Influenza A (H1N1) Virus in Pediatric and Adult Recipients of Seasonal Trivalent Inactivated Influenza Vaccines., and Table 2 in the Supplementary Appendix). Among 13 samples from a subgroup of children between the ages of 5 to 9 years, in which prevaccination antibodies to the seasonal H1N1 virus were evident, the GMT of antibodies against 2009 H1N1 was 10; titers of 40 or more were observed in only 1 child (8%) in this age group. After vaccination with seasonal vaccine, the GMT of antibodies against 2009 H1N1 did not increase by a factor of four or more in any of the 55 children who received trivalent inactivated vaccine, although a robust response to seasonal vaccine strains was detected in 67 to 100% of the children. Likewise, no seroconversion to antibodies against 2009 H1N1 was detected in any of the 24 children between the ages of 6 months to 9 years who were vaccinated with live attenuated influenza vaccine (Table 2 in the Supplementary Appendix). However, only 7 of 24 recipients of the live attenuated vaccine (29%) had an increase by a factor of four or more in the antibody titer against the seasonal vaccine strain, and all the children had a lower postvaccination GMT, as compared with recipients of the inactivated vaccine, as reported previously.14 Vaccination of 344 adults with inactivated seasonal vaccine resulted in seroconversion against the seasonal H1N1 vaccine strain in 65 of 83 adults between the ages of 18 and 40 years (78%), in 111 of 148 of those between the ages of 18 and 64 years (75%), and in 9 of 49 (18%) and 34 of 63 (54%) of those 60 years of age or older, depending on the year (Table 1). Seroconversion to antibodies against 2009 H1N1 was observed in 10 of 83 adults (12%) between the ages of 18 and 40 years, in 33 of 148 adults (22%) between the ages of 18 and 64 years, and in 3 of 63 (5%) or none of 50 adults 60 years of age or older, depending on the year. The ratios between the GMT after vaccination to the GMT before vaccination for the response to 2009 H1N1 ranged from 1 to 2 in both the adult and older-adult age groups, as compared with the GMT ratios observed for the seasonal H1N1 vaccine component ranging from 2 to 19 (Table 3 in the Supplementary Appendix). However, 6 to 7% of 231 adults and up to one third of 113 older adults had prevaccination microneutralization antibody titers of 160 or more against 2009 H1N1. Vaccination with the 2007–2008 seasonal vaccine, but not with the 2008–2009 seasonal vaccine, resulted in a modest boost in the cross-reactive antibody response, which was probably driven by the higher prevaccination GMTs detected in 2007–2008 samples, as compared with 2008–2009 samples. Interestingly, the prevaccination antibody GMT of older adults against 2009 H1N1 was significantly higher than the GMT in the seasonal 2007–2008 H1N1 vaccine component (P<0.001). A similar trend was seen with the prevaccination GMT of older adults who received the seasonal 2008–2009 vaccine. Vaccination of adults with either the 2007–2008 or 2008–2009 live attenuated vaccine resulted in only a marginal effect on the levels of the microneutralization antibody titer against the respective seasonal H1N1 vaccine strains and no effect on the levels of antibodies against 2009 H1N1 (Table 3 in the Supplementary Appendix).
We next determined whether the seasonal inactivated vaccine that was formulated with oil-in-water adjuvants would enhance the level of cross-reactive antibody response to 2009 H1N1 when administered as a single dose to adults or as two doses to children. Only a modest increase in cross-reactive antibody response against 2009 H1N1 was detected in serum samples from 45 children between the ages of 6 months and 59 months who received the 2008–2009 inactivated vaccine formulated with an oil-in-water adjuvant (Table 1). Although seroconversion was detected in 43 children (96%) and 100% had a titer of 40 or more against the seasonal H1N1 component, seroconversion to antibodies against 2009 H1N1 occurred in only 1 child (2%), and 2 children (4%) had postvaccination antibody titers of 40 or more against 2009 H1N1. In adults and older adults, although a formulation of the seasonal inactivated vaccines with oil-in-water adjuvants provided either a dose-sparing benefit or an enhanced rate of seroconversion to the seasonal H1N1 vaccine component, the adjuvanted vaccines showed no substantial enhancement of the cross-reactive antibody response to 2009 H1N1 (Table 4 in the Supplementary Appendix).
Cross-Reactive Antibody Response from Previous Infection or Vaccination
To further investigate the age distribution of cross-reactive neutralizing antibodies against 2009 H1N1 in U.S. populations, we tested a collection of 417 samples from anonymous donors born between 1880 and 2004 for antibodies against 2009 H1N1. The peak of antibody responses, presented as the frequency of titer achievement, occurred in 11 donors who were born between 1910 and 1929 (100% with titers of 80 or more), although the study was limited by the small number of samples from donors born between 1880 and 1920 (Figure 1Figure 1
Neutralizing Antibody Titers against the 2009 Pandemic H1N1 Virus among Serum Donors, According to Birth Decade (1880–2000).). The cumulative GMT, which includes data from subjects born in any one decade and those born in previous decades, peaked in the 1920s and gradually declined afterward. Approximately 39 of 115 subjects (34%) who were born before 1950 had antibody titers of 80 or more against 2009 H1N1. However, only 4 of 107 subjects (4%) who were born after 1980 had titers of 40 or more.In 1976, approximately 20% of the U.S. population was immunized with the A/NJ/76 (H1N1) vaccine.15 We tested archived serum samples from 83 adults who were at least 25 years of age at the time that the sample was obtained and who had received one dose (400 chicken-cell agglutinating units) of a monovalent, split A/NJ/76 vaccine.16 Vaccination with the A/NJ/76 vaccine resulted in seroconversion to antibodies against A/NJ/76 virus in 67 subjects (81%) and a corresponding seroconversion to antibodies against 2009 H1N1 in 45 subjects (54%) (Table 5 in the Supplementary Appendix). Whereas 59 subjects (71%) achieved a postvaccination microneutralization antibody titer of 160 or more against the vaccine strain, 52 subjects (63%) achieved a postvaccination antibody titer of 160 or more against 2009 H1N1. These results showed that vaccination with the A/NJ/76 vaccine of persons who were primed by previous natural infection with influenza H1N1 virus led to the generation of serum antibodies that were broadly cross-reactive against 2009 H1N1.
Discussion
The data from our study indicate that vaccination with contemporary seasonal influenza vaccines, even when formulated with oil-in-water adjuvants, provide little or no benefit to any age group with respect to an increase in cross-reactive neutralizing antibodies against 2009 H1N1. These findings are consistent with the substantial degree of genetic divergence of the pandemic H1N1 viruses of swine origin, as compared with recent seasonal human H1N1 viruses.2 Although adjuvants enhanced serologic cross-clade reactivity of H5N1 two-dose vaccines, the degree of genetic identity between H5N1 clades is considerably higher (96 to 97%) than that for the pandemic H1N1 and seasonal H1N1 viruses.17-19
Children had little evidence of cross-reactive antibodies to 2009 H1N1, but some degree of preexisting immunity to 2009 H1N1 existed, especially in older adults. Although the relatively small number of serum samples from pediatric trials was a limitation of our study, none of the seasonal vaccine formulations that we tested elicited a cross-reactive antibody response against 2009 H1N1. Subjects who were born before 1930, who were probably exposed to a 1918-like H1N1 virus, had the highest titers against 2009 H1N1. The presence of antibody titers of 80 or more against 2009 H1N1 in 34% of subjects who were born before 1950 is consistent with the higher frequency of prevaccination antibody titers of 80 or more against 2009 H1N1 that were detected in older adults in studies of seasonal influenza vaccines in the United States. These data suggest that exposure to a 1918-like H1N1 virus contributed to the induction of the cross-reactive antibody response to 2009 H1N1.
Furthermore, the data confirm the presence of some level of cross-reactive antibody in persons 60 years or more of age and the lack of such antibody in children and adults. This finding is consistent with those of previous studies showing a similar effect for birth-year cohort on serum antibody responses to classical swine H1N1 viruses. These studies also showed that survivors of the 1918 pandemic had antibodies that neutralized the closely related A/swine/Iowa/30 virus.6,20-24 Furthermore, present-day subjects who were exposed to the 1918 virus had high-affinity neutralizing antibodies against epitopes on the hemagglutinin globular head that are conserved in both 1918 and A/swine/Iowa/30 viruses but not in human H1N1 viruses that circulated in the 1940s.25 Recently, Itoh et al.26 reported similar findings in that serum donors from Japan who were probably exposed to the 1918 virus or a closely related H1N1 virus had high levels of neutralizing antibodies against 2009 H1N1. However, in contrast to our findings, no appreciable cross-reactive antibody was detected in subjects born after 1920. These differences between the two studies may reflect differences in methodology or vaccination coverage rates in older adults, including receipt of the 1976 swine influenza vaccine in older adults in the United States. Likewise, the overall increased prevaccination titers for antibodies against 2009 H1N1 that we observed in older adults in the United States, as compared with their European counterparts, may reflect similar disparities in influenza vaccination history (Table 1).
Priming by previous natural infection with human H1N1 viruses in adults who were immunized with swine-origin A/NJ/76 (H1N1) virus vaccine probably contributed to the observed cross-reactive antibody response against 2009 H1N1. Serum samples from a small number of children between the ages of 6 months and 4 years who had had no previous exposure to the H1N1 virus and who received two doses (40 to 200 chicken-cell agglutinating units) of the A/NJ/76 vaccine had only modest cross-reactive antibodies against 2009 H1N1. (Only 2 of 10 subjects had seroconversion with a microneutralization antibody titer of 40 or more against 2009 H1N1, although all 10 children had seroconversion to antibodies against the A/NJ/76 virus.) It is possible that residual antibody that was induced by A/NJ/76 vaccination of adults may contribute to the observed cross-reactive antibody response in some older adults.
In a representative proportion of U.S. subjects with laboratory-confirmed 2009 H1N1 infection for whom age was known, approximately 79% of cases occurred in subjects who were under the age of 30 years, whereas only 2% of confirmed cases were identified in those who were over 60 years of age. Therefore, the age distribution of laboratory-confirmed 2009 H1N1 infections is consistent with the observed lack of preexisting antibodies in children and adults and suggests one reason that older adults represent a minor proportion of reported cases: that cross-reactive antibody responses may provide protection against disease in this age group. Although we assessed only neutralizing antibody against 2009 H1N1 hemagglutinin, it is possible that heterotypic immunity to influenza from antibody against the neuraminidase or cellular responses to highly conserved viral epitopes may also contribute to the apparent protective effect in older adults.27 Another possibility is that 2009 H1N1 has not yet spread to this older age group from populations that lack cross-reactive antibodies.
It remains clear that optimal protection against 2009 H1N1 in persons of all ages will be achieved with the development of a strain-specific pandemic vaccine. Whether a one-dose or a two-dose vaccine regimen is needed to adequately immunize various age groups and whether the use of adjuvants will broaden the immune response against 2009 H1N1 if drifted strains emerge or provide dose-sparing benefits will ultimately be determined by the results of clinical studies that are now under way.
The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC.
Dr. Hancock reports receiving research support from GlaxoSmithKline and Juvaris BioTherapeutics; Dr. Lu, research support from Juvaris BioTherapeutics; and Dr. Katz, research support from GlaxoSmithKline. No other conflict of interest relevant to this article was reported.
This article (10.1056/NEJMoa0906453) was published on September 10, 2009, at NEJM.org.
We thank our colleagues who shared serum samples from vaccine trials conducted under the guidance of their institutions: Robert B. Couch, Baylor College of Medicine; Zhiping Ye, Center for Biologics Evaluation and Research, Food and Drug Administration; Ventzi Vassilev, GlaxoSmithKline; Thomas P. Monath, Juvaris BioTherapeutics; Kathleen Coelingh, MedImmune; Brian R. Murphy and Linda C. Lambert, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Theodore F. Tsai, Novartis Vaccines and Diagnostics; Robert B. Belshe, Saint Louis University; Cornelia L. Dekker, Harry B. Greenberg, and David B. Lewis, Stanford University School of Medicine; Arnold S. Monto, University of Michigan School of Public Health; and Peter F. Wright, John V. Williams, and Kathryn M. Edwards, Vanderbilt University School of Medicine; Patrick Blair, Naval Health Research Center, San Diego, for facilitating access to the 2009 H1N1 virus; William M. Marine, formerly at Emory University School of Medicine, for locating the archived samples from anonymous donors collected in 1971; our colleagues at the CDC who contributed to virus isolation, sequence information, and the collection of donor samples and who provided critical assistance in handling incoming serum collections: Amanda Balish, Suzette L. Bartley, J. Brad Bowzard, Susan P. Danner, William G. Davis, Rebecca Garten, Deborah Lee, Robyn A. Stoddard, and Mayim E. Wiens; and Christopher Freedman, Lindsay F. Killmaster, and Ashley L. Sabol of other branches of the CDC for their volunteer help.
Source Information
From the Influenza Division, National Center for Immunization and Respiratory Diseases (K.H., V.V., X.L., W.Z., E.N.B., H.S., F.L., L.D., P.M.G., T.L.B., N.J.C., T.M.T., J.M.K.), and the Division of Global AIDS, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (J.R.D.) — all at the Centers for Disease Control and Prevention (CDC), Atlanta.
Address reprint requests to Dr. Katz at the Influenza Division, CDC, 1600 Clifton Rd., Atlanta, GA 30333, or at jkatz@cdc.gov.
- References
References
1
Novel Swine-Origin Influenza A (H1N1) Virus Investigation TeamEmergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;360:2605-2615[Erratum, N Engl J Med 2009;361:102.]
Full Text | Web of Science | Medline2
Garten RJ ,Davis CT ,Russell CA , et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009;325:197-201
CrossRef | Web of Science | Medline3
Newman AP ,Reisdorf E ,Beinemann J , et al. Human case of swine influenza A (H1N1) triple reassortant virus infection, Wisconsin. Emerg Infect Dis 2008;14:1470-1472
CrossRef | Web of Science | Medline4
Shinde V ,Bridges CB ,Uyeki TM , et al. Triple-reassortant swine influenza A (H1) in humans in the United States, 2005-2009. N Engl J Med 2009;360:2616-2625[Erratum, N Engl J Med 2009;361:102.]
Full Text | Web of Science | Medline5
Nelson MI ,Viboud C ,Simonsen L , et al. Multiple reassortment events in the evolutionary history of H1N1 influenza A virus since 1918. PLoS Pathog 2008;4:e1000012-e1000012
CrossRef | Web of Science | Medline6
Dowdle WR . Pandemic influenza: confronting a re-emergent threat: the 1976 experience. J Infect Dis 1997;176:Suppl 1:S69-S72
CrossRef | Medline7
Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep 2009;58:521-524
Medline8
Marine WM ,Thomas JE . Age-related response to 1000 CCA unit zonally purified, inactivated influenza vaccines in volunteers in the U.S.A. Postgrad Med J 1973;49:164-168
CrossRef | Web of Science | Medline9
Kendal AP, Pereira MS, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillance. Atlanta: Centers for Disease Control, 1982.
10
Rowe T ,Abernathy RA ,Hu-Primmer J , et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999;37:937-943
Web of Science | Medline11
de Jong JC ,Palache AM ,Beyer WEP ,Rimmelzwaan GF ,Boon ACM ,Osterhaus ADME . Haemagglutination-inhibiting antibodies to influenza virus. Dev Biol (Basel) 2003;115:63-73
Medline12
Potter CW ,Oxford JS . Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75
Web of Science | Medline13
Fox JP ,Hall CE ,Cooney MK ,Foy HM . Influenza virus infections in Seattle families, 1975-1979. I. Study design, methods and the occurrence of infections by time and age. Am J Epidemiol 1982;116:212-227
Web of Science | Medline14
Sasaki S ,Jaimes MC ,Holmes TH , et al. Comparison of the influenza virus-specific effector and memory B-cell responses to immunization of children and adults with live attenuated or inactivated influenza virus vaccines. J Virol 2007;81:215-228
CrossRef | Web of Science | Medline15
Sencer DJ ,Millar JD . Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 2006;12:29-33
CrossRef | Web of Science | Medline16
Massicot J ,Murphy BR . Comparison of the hemagglutination-inhibiting and neutralizing antibody responses of volunteers given 400 chick cell-agglutinating units of influenza A/New Jersey/76 split-virus vaccine. J Infect Dis 1977;136:Suppl:S472-S474
CrossRef | Web of Science | Medline17
Leroux-Roels I ,Bernhard R ,Gerard P ,Drame M ,Hanon E ,Leroux-Roels G . Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008;3:e1665-e1665
CrossRef | Web of Science | Medline18
Stephenson I ,Bugarini R ,Nicholson KG , et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210-1215
CrossRef | Web of Science | Medline19
Stephenson I ,Nicholson KG ,Hoschler K , et al. Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1. N Engl J Med 2008;359:1631-1633
Full Text | Web of Science | Medline20
Davenport FM ,Hennessy AV ,Francis T Jr . Epidemiologic and immunologic significance of age distribution of antibody to antigenic variants of influenza virus. J Exp Med 1953;98:641-656
CrossRef | Web of Science | Medline21
Shope RE . The incidence of neutralizing antibodies for swine influenza virus in the sera of human beings of different ages. J Exp Med 1936;63:669-684
CrossRef | Web of Science | Medline22
Taubenberger JK ,Reid AH ,Janczewski TA ,Fanning TG . Integrating historical, clinical and molecular genetic data in order to explain the origin and virulence of the 1918 Spanish influenza virus. Philos Trans R Soc Lond B Biol Sci 2001;356:1829-1839
CrossRef | Web of Science | Medline23
Tumpey TM ,Garcia-Sastre A ,Taubenberger JK ,Palese P ,Swayne DE ,Basler CF . Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A 2004;101:3166-3171
CrossRef | Web of Science | Medline24
Cuneo-Crovari P ,Gasparini R ,Pellegrino C . Sero-epidemiological survey on human and swine influenza A: situation at the onset of summer 1976. Boll Ist Sieroter Milan 1976;55:463-470
Medline25
Yu X ,Tsibane T ,McGraw PA , et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivors. Nature 2008;455:532-536
CrossRef | Web of Science | Medline26
Itoh Y ,Shinya K ,Kiso M , et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009;460:1021-1025
Web of Science | Medline27
Rimmelzwaan GF ,McElhaney JE . Correlates of protection: novel generations of influenza vaccines. Vaccine 2008;26:Suppl 4:D41-D44
CrossRef | Web of Science | Medline
- Citing Articles (281)
Citing Articles
1
Joanne Simpson, Mick Roberts. (2012) Modelling heterogeneous host immune response in a multi-strain system. Journal of Theoretical Biology 304, 60-65
CrossRef2
J.C. Rahamat-Langendoen, E.D. Tutuhatunewa, E.H. Schölvinck, E. Hak, M. Koopmans, H.G.M. Niesters, A. Riezebos-Brilman. (2012) Influenza in the immediate post-pandemic era: A comparison with seasonal and pandemic influenza in hospitalized patients. Journal of Clinical Virology 54:2, 135-140
CrossRef3
Tadashi Kikuchi, Kiyoko Iwatsuki-Horimoto, Eisuke Adachi, Michiko Koga, Hitomi Nakamura, Noriaki Hosoya, Ai Kawana-Tachikawa, Tomohiko Koibuchi, Toshiyuki Miura, Takeshi Fujii, Yoshihiro Kawaoka, Aikichi Iwamoto. (2012) Improved neutralizing antibody response in the second season after a single dose of pandemic (H1N1) 2009 influenza vaccine in HIV-1-positive adults. Vaccine 30:26, 3819-3823
CrossRef4
Yeon-Kyeng Lee, Yunhyung Kwon, Dong-Wook Kim, Kyung Min Song, Heeyeon Cho, Chang-Hoon Kim, Un-Yeong Go, Geun-Ryang Bae, Jong-Koo Lee. (2012) 2009-2010 novel influenza A (H1N1) vaccination coverage in the Republic of Korea. American Journal of Infection Control 40:5, 481-483
CrossRef5
Antonia Sinisi, Maximilian Wei-Lin Popp, John Antos, Werner Pansegrau, Silvana Savino, Mikkel Nissum, Rino Rappuoli, Hidde L. Ploegh, Ludovico Buti. (2012) Development of an Influenza virus protein array using Sortagging technology. Bioconjugate Chemistry120517020549003
CrossRef6
Salaheddin M. Mahmud, Paul Van Caeseele, Gregory Hammond, Carol Kurbis, Tim Hilderman, Lawrence Elliott. (2012) No Association between 2008–09 Influenza Vaccine and Influenza A(H1N1)pdm09 Virus Infection, Manitoba, Canada, 2009. Emerging Infectious Diseases 18:5, 801-810
CrossRef7
Jiehui Kevin Yin, Maria Yui Kwan Chow, Gulam Khandaker, Catherine King, Peter Richmond, Leon Heron, Robert Booy. (2012) Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: Systematic review and meta-analyses. Vaccine 30:21, 3209-3222
CrossRef8
Cheng-Wei Liu, Jeremy J.W. Chen, Chia-Chen Kang, Chia-Hui Wu, Jinn-Chin Yiu. (2012) Transgenic lettuce (Lactuca sativa L.) expressing H1N1 influenza surface antigen (neuraminidase). Scientia Horticulturae 139, 8-13
CrossRef9
Chien-Ching Hung, Tai-Ling Zhao, Hsin-Yun Sun, Yi-Fang Yang, Yi-Ching Su, Shu-Fang Chang, Wen-Chun Liu, Cheng-Hsin Wu, Sui-Yuan Chang, Shan-Chwen Chang. (2012) Seroepidemiology of novel influenza A (H1N1) infection among HIV-infected patients in the era of highly active antiretroviral therapy. Journal of Microbiology, Immunology and Infection
CrossRef10
Steven Rockman, Deborah J. Middleton, Martin J. Pearse, Ian G. Barr, Sue Lowther, Lorena E. Brown. (2012) Control of pandemic (H1N1) 2009 influenza virus infection of ferret lungs by non-adjuvant-containing pandemic and seasonal vaccines. Vaccine 30:24, 3618-3623
CrossRef11
Luke R. Le Grand, Michaela White, Evan B. Siegel, Ross T. Barnard. 2012. Recombinant Vaccines: Development, Production, and Application. , 423-449.
CrossRef12
William R Mulley, Kumar Visvanathan, Aeron C Hurt, Fiona G Brown, Kevan R Polkinghorne, Tasoula Mastorakos, Michelle C Lewicki, Rhonda L Stuart, Sven-Jean Tan, Roy Chean, Peter G Kerr, John Kanellis. (2012) Mycophenolate and lower graft function reduce the seroresponse of kidney transplant recipients to pandemic H1N1 vaccination. Kidney International
CrossRef13
Emi Inoue, Masahiro Ieko, Nobuhiko Takahashi, Yoshiaki Osawa, Katsunori Okazaki. (2012) Phylogenetic analyses of pandemic influenza A (H1N1) virus in university students at Tobetsu, Hokkaido, Japan. Microbiology and Immunology 56:4, 273-279
CrossRef14
Abdulaziz Al-Mahrezi, Nafisa Samir, Ibrahim Al-Zakwani, Zakaria Al-Muharmi, Abdulla Balkhair, Mohammed Al-Shafaee. (2012) Clinical characteristics of influenza A H1N1 versus other influenza-like illnesses amongst outpatients attending a university health center in Oman. International Journal of Infectious Diseases
CrossRef15
Elisa Faenzi, Luisanna Zedda, Monia Bardelli, Fabiana Spensieri, Erica Borgogni, Gianfranco Volpini, Francesca Buricchi, Franco Laghi Pasini, Pier Leopoldo Capecchi, Fabio Montanaro, Riccardo Belli, Maria Lattanzi, Simona Piccirella, Emanuele Montomoli, Syed Sohail Ahmed, Rino Rappuoli, Giuseppe Del Giudice, Oretta Finco, Flora Castellino, Grazia Galli. (2012) One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine
CrossRef16
Karen L. Laurie, Patricia Huston, Steven Riley, Jacqueline M. Katz, Donald J. Willison, John S. Tam, Anthony W. Mounts, Katja Hoschler, Elizabeth Miller, Kaat Vandemaele, Eeva Broberg, Maria D. Van Kerkhove, Angus Nicoll. (2012) Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting. Influenza and Other Respiratory Virusesno-no
CrossRef17
W. Liang, L. Feng, C. Xu, N. Xiang, Y. Zhang, Y. Shu, H. Wang, H. Luo, H. Yu, X. Liang, D. Li, C.-K. Lee, Z. Feng, Y. Hou, Y. Wang, Z. Chen, W. Yang. (2012) Response to the first wave of pandemic (H1N1) 2009: Experiences and lessons learnt from China. Public Health
CrossRef18
Hartmut J. Ehrlich, Markus Müller, Herwig Kollaritsch, Fritz Pinl, Bernhard Schmitt, Markus Zeitlinger, Alexandra Loew-Baselli, Thomas R. Kreil, Otfried Kistner, Daniel Portsmouth, Sandor Fritsch, Friedrich Maritsch, Gerald Aichinger, Borislava G. Pavlova, P. Noel Barrett. (2012) Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine. Vaccine
CrossRef19
Yong He, Afsheen Abid, Robert Fisher, Nancy Eller, Malgorzata Mikolajczyk, Robert C. Welliver, Aleta B. Bonner, Dorothy E. Scott, Jennifer L. Reed. (2012) Mucosal antibody responses are directed by viral burden in children with acute influenza infection. Influenza and Other Respiratory Virusesno-no
CrossRef20
Glendie Marcelin, Matthew R. Sandbulte, Richard J. Webby. (2012) Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Reviews in Medical Virologyn/a-n/a
CrossRef21
José Ramón Paño-Pardo, Diego Viasus, Jerónimo Pachón, Antoni Campins, Francisco López-Medrano, Aroa Villoslada, Manuel Gutiérrez-Cuadra, Tomás Pumarola, María Dolores del Toro, José A. Oteo, Joaquin Martínez-Montauti, Juan Gutiérrez-Aroca, Ferrán Segura, Jordi Carratalà, . (2012) Pandemic 2009 A(H1N1) Infection Requiring Hospitalization of Elderly Spanish Adults. Journal of the American Geriatrics Societyn/a-n/a
CrossRef22
Naveed Z. Janjua, Danuta M. Skowronski, Travis S. Hottes, William Osei, Evan Adams, Martin Petric, Marcus Lem, Patrick Tang, Gaston De Serres, David M. Patrick, David Bowering. (2012) Transmission dynamics and risk factors for pandemic H1N1-related illness: outbreak investigation in a rural community of British Columbia, Canada. Influenza and Other Respiratory Virusesno-no
CrossRef23
T Kuiken, B Riteau, RAM Fouchier, GF Rimmelzwaan. (2012) Pathogenesis of influenza virus infections: the good, the bad and the ugly. Current Opinion in Virology
CrossRef24
A. Rodríguez, L. Álvarez-Rocha, J.M. Sirvent, R. Zaragoza, M. Nieto, A. Arenzana, P. Luque, L. Socías, M. Martín, D. Navarro, J. Camarena, L. Lorente, S. Trefler, L. Vidaur, J. Solé-Violán, F. Barcenilla, A. Pobo, J. Vallés, C. Ferri, I. Martín-Loeches, E. Díaz, D. López, M.J. López-Pueyo, F. Gordo, F. del Nogal, A. Marqués, S. Tormo, M.P. Fuset, F. Pérez, J. Bonastre, B. Suberviola, E. Navas, C. León. (2012) Recommendations of the Infectious Diseases Work Group (GTEI) of the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) and the Infections in Critically Ill Patients Study Group (GEIPC) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) for the diagnosis and treatment of influenza A/H1N1 in seriously ill adults admitted to the Intensive Care Unit. Medicina Intensiva (English Edition) 36:2, 103-137
CrossRef25
Vesna Šubelj, Katarina Prosenc, Maja Sočan. (2012) Seroprevalence study of antibodies against influenza A(H1N1) 2009 virus after the second pandemic wave in Slovenia. Wiener klinische Wochenschrift
CrossRef26
J. Delangue, N. Salez, L. Ninove, A. Kieffer, C. Zandotti, M. Seston, B. Lina, A. Nougairede, R. Charrel, A. Flahault, X. de Lamballerie. (2012) Serological study of the 2009 pandemic due to influenza A H1N1 in the metropolitan French population. Clinical Microbiology and Infection 18:2, 177-183
CrossRef27
D. M. Weinberger, L. Simonsen, R. Jordan, C. Steiner, M. Miller, C. Viboud. (2012) Impact of the 2009 Influenza Pandemic on Pneumococcal Pneumonia Hospitalizations in the United States. Journal of Infectious Diseases 205:3, 458-465
CrossRef28
Shivashni S. Gaundar, Emily Blyth, Leighton Clancy, Renee M. Simms, Chun K. K. Ma, David J. Gottlieb. (2012) In vitro generation of influenza-specific polyfunctional CD4 + T cells suitable for adoptive immunotherapy. Cytotherapy 14:2, 182-193
CrossRef29
Alexanderyn Burmaa, Sosorbaramyn Tsatsral, Takashi Odagiri, Akira Suzuki, Hitoshi Oshitani, Pagbajabyn Nymadawa. (2012) Cumulative incidence of pandemic influenza A (H1N1) 2009 by a community-based serological cohort study in Selenghe Province, Mongolia. Influenza and Other Respiratory Virusesno-no
CrossRef30
R. B. Couch, R. L. Atmar, L. M. Franco, J. M. Quarles, D. Nino, J. M. Wells, N. Arden, S. Cheung, J. W. Belmont. (2012) Prior Infections With Seasonal Influenza A/H1N1 Virus Reduced the Illness Severity and Epidemic Intensity of Pandemic H1N1 Influenza in Healthy Adults. Clinical Infectious Diseases 54:3, 311-317
CrossRef31
D. Frasca, A. Diaz, M. Romero, M. Phillips, N. V. Mendez, A. M. Landin, B. B. Blomberg. (2012) Unique biomarkers for B-cell function predict the serum response to pandemic H1N1 influenza vaccine. International Immunology
CrossRef32
Tanushree Dangi, Amita Jain. (2012) Influenza Virus: A Brief Overview. Proceedings of the National Academy of Sciences, India Section B: Biological Sciences
CrossRef33
Y.-H. Kim, J.-K. Kim, D.-J. Kim, J.-H. Nam, S.-M. Shim, Y.-K. Choi, C.-H. Lee, H. Poo. (2012) Diet-Induced Obesity Dramatically Reduces the Efficacy of a 2009 Pandemic H1N1 Vaccine in a Mouse Model. Journal of Infectious Diseases 205:2, 244-251
CrossRef34
John M. Wood, Diane Major, Alan Heath, Robert W. Newman, Katja Höschler, Iain Stephenson, Tristan Clark, Jacqueline M. Katz, Maria C. Zambon. (2012) Reproducibility of serology assays for pandemic influenza H1N1: Collaborative study to evaluate a candidate WHO International Standard. Vaccine 30:2, 210-217
CrossRef35
Luis Fernando A. Camargo, Tainá V. de Sandes-Freitas, Camila D. R. Silva, Carolina D. Bittante, Gislaine Ono, Luci Corrêa, Moacyr Silva, Nancy Cristina J. Bellei, Janaína M. Goto, Eduardo A. S. Medeiros, Pollyane S. Gomes, José O. Medina-Pestana. (2012) Morbimortality of Pandemic Influenza A H1N1 Infection in Kidney Transplant Recipients Requiring Hospitalization: A Comparative Analysis With Nonimmunocompromised Patients. Transplantation 93:1, 69-72
CrossRef36
Jessica C. Seidman, Stephanie A. Richard, Cécile Viboud, Mark A. Miller. (2012) Quantitative review of antibody response to inactivated seasonal influenza vaccines. Influenza and Other Respiratory Viruses 6:1, 52-62
CrossRef37
Seth L. Toback, Richard Beigi, Patricia Tennis, Frangiscos Sifakis, Brian Calingaert, Christopher S. Ambrose. (2012) Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza and Other Respiratory Viruses 6:1, 44-51
CrossRef38
Kathryn Glass, Heath Kelly, Geoffry Norman Mercer. (2012) Pandemic Influenza H1N1. Epidemiology 23:1, 86-94
CrossRef39
Anna Vilella, Beatriz Serrano, Maria A. Marcos, Anna Serradesanferm, Josep Mensa, Edward Hayes, Andres Anton, Jose Rios, Tomas Pumarola, Antoni Trilla. (2012) Pandemic Influenza A(H1N1) Outbreak Among a Group of Medical Students Who Traveled to the Dominican Republic. Journal of Travel Medicine 19:1, 9-14
CrossRef40
Libo Dong, Feng Liu, Jeffery Fairman, David K. Hong, David B. Lewis, Thomas Monath, John F. Warner, Jessica A. Belser, Jenish Patel, Kathy Hancock, Jacqueline M. Katz, Xiuhua Lu. (2012) Cationic liposome–DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice. Vaccine 30:2, 254-264
CrossRef41
Julián Olalla, Fernando de Ory, Inmaculada Casas, Alfonso del Arco, Natalia Montiel, Francisco Rivas-Ruiz, Javier de la Torre, José Luis Prada, Fernando Fernández, Javier García-Alegría. (2012) Seroprevalence of antibodies to the influenza A (H1N1) virus among healthcare workers prior to the 2009 pandemic peak. Enfermedades Infecciosas y Microbiología Clínica
CrossRef42
Curtis Cooper, Marina Klein, Sharon Walmsley, David Haase, Donna MacKinnon-Cameron, Kimberley Marty, Yan Li, Bruce Smith, Scott Halperin, Barb Law, David Scheifele. (2012) High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1<sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. HIV Clinical Trials 13:1, 23-32
CrossRef43
Anna M. Iorio, Onelia Bistoni, Massimiliano Galdiero, Enrica Lepri, Barbara Camilloni, Anna M. Russano, Mariella Neri, Michela Basileo, Fabrizio Spinozzi. (2012) Influenza viruses and cross-reactivity in healthy adults: Humoral and cellular immunity induced by seasonal 2007/2008 influenza vaccination against vaccine antigens and 2009 A(H1N1) pandemic influenza virus. Vaccine
CrossRef44
A. Rodríguez, L. Álvarez-Rocha, J.M. Sirvent, R. Zaragoza, M. Nieto, A. Arenzana, P. Luque, L. Socías, M. Martín, D. Navarro, J. Camarena, L. Lorente, S. Trefler, L. Vidaur, J. Solé-Violán, F. Barcenilla, A. Pobo, J. Vallés, C. Ferri, I. Martín-Loeches, E. Díaz, D. López, M.J. López-Pueyo, F. Gordo, F. del Nogal, A. Marqués, S. Tormo, M.P. Fuset, F. Pérez, J. Bonastre, B. Suberviola, E. Navas, C. León. (2012) Recomendaciones del Grupo de Trabajo Enfermedades Infecciosas (GTEI) de la Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) y el Grupo de Estudio de Infecciones en el Paciente Crítico (GEIPC) de la Sociedad Española de Enfermedades Infecciosas y Microbiología clínica (SEIMC) para el diagnóstico y tratamiento de la gripe A/H1N1 en pacientes adultos graves hospitalizados en las Unidades de Cuidados Intensivos. Medicina Intensiva
CrossRef45
Liana Martirosyan, W. John Paget, Pernille Jorgensen, Caroline S Brown, Tamara J Meerhoff, Dmitriy Pereyaslov, Joshua A Mott. (2012) The community impact of the 2009 influenza pandemic in the WHO European Region: a comparison with historical seasonal data from 28 countries. BMC Infectious Diseases 12:1, 36
CrossRef46
D. Viasus, E. Cordero, J. Rodríguez-Baño, J. A. Oteo, A. Fernández-Navarro, L. Ortega, I. Gracia-Ahufinger, M. C. Fariñas, E. García-Almodovar, A. Payeras, J. R. Paño-Pardo, E. Muñez-Rubio, J. Carratalà, . (2012) Changes in epidemiology, clinical features and severity of influenza A (H1N1) 2009 pneumonia in the first post-pandemic influenza season. Clinical Microbiology and Infectionno-no
CrossRef47
Curtis Cooper, Marina Klein, Sharon Walmsley, David Haase, Donna MacKinnon-Cameron, Kimberley Marty, Yan Li, Bruce Smith, Scott Halperin, Barb Law, David Scheifele. (2012) High-Level Immunogenicity Is Achieved Vaccine With Adjuvanted Pandemic H1N1<sub>2009</sub> and Improved With Booster Dosing in a Randomized Trial of HIV-Infected Adults. HIV Clinical Trials 13:1, 23-32
CrossRef48
KIYOSHI TACHIKI, MIKA KURAMOTO, MISUZU KANEKO, MAYUKO NAWA, YUSUKE NIWA, MASAE ITOH. (2012) Capture of Influenza Viruses and Prevention of Their Infection by Coral Mineral Powder (Sango Mineral Powder). Biocontrol Science 17:1, 17-25
CrossRef49
Dong Hyuk Shin, Sang Kuk Han, Pil Cho Choi, Hee-Yeon Woo. (2012) Conventional blood tests in predicting influenza A (H1N1) rapidly. Scandinavian Journal of Clinical & Laboratory Investigation 72:3, 197
CrossRef50
Weijia Wang, Amorsolo L. Suguitan, James Zengel, Zhongying Chen, Hong Jin. (2012) Generation of recombinant pandemic H1N1 influenza virus with the HA cleavable by bromelain and identification of the residues influencing HA bromelain cleavage. Vaccine 30:5, 872-878
CrossRef51
Hana Hakim, Kim J. Allison, Lee-Ann Van De Velde, Yimei Li, Patricia M. Flynn, Jonathan A. McCullers. (2012) Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults. Vaccine 30:5, 879-885
CrossRef52
S. Khurana, N. Verma, K. R. Talaat, R. A. Karron, H. Golding. (2011) Immune Response Following H1N1pdm09 Vaccination: Differences in Antibody Repertoire and Avidity in Young Adults and Elderly Populations Stratified by Age and Gender. Journal of Infectious Diseases
CrossRef53
H. Xie, X. Li, J. Gao, Z. Lin, X. Jing, E. Plant, O. Zoueva, M. C. Eichelberger, Z. Ye. (2011) Revisiting the 1976 "Swine Flu" Vaccine Clinical Trials: Cross-reactive Hemagglutinin and Neuraminidase Antibodies and Their Role in Protection Against the 2009 H1N1 Pandemic Virus in Mice. Clinical Infectious Diseases 53:12, 1179-1187
CrossRef54
Suresh Pallikkuth, Sudheesh Pilakka Kanthikeel, Sandra Y. Silva, Margaret Fischl, Rajendra Pahwa, Savita Pahwa. (2011) Innate immune defects correlate with failure of antibody responses to H1N1/09 vaccine in HIV-infected patients. Journal of Allergy and Clinical Immunology 128:6, 1279-1285
CrossRef55
T. Ilyicheva, I. Susloparov, A. Durymanov, A. Romanovskaya, K. Sharshov, O. Kurskaya, M. Ignashkina, A. Shestopalov. (2011) Influenza A/H1N1pdm virus in Russian Asia in 2009–2010. Infection, Genetics and Evolution 11:8, 2107-2112
CrossRef56
Karen Trevennec, Lucas Leger, Faouzi Lyazrhi, Eugénie Baudon, Chung Yan Cheung, François Roger, Malik Peiris, Jean-Michel Garcia. (2011) Transmission of pandemic influenza H1N1 (2009) in Vietnamese swine in 2009-2010. Influenza and Other Respiratory Virusesno-no
CrossRef57
Remko Enserink, Adam Meijer, Frederika Dijkstra, Birgit Benthem, Jenny T. Steen, Anja Haenen, Hans Delden, Herman Cools, Marianne Sande, Marie-Jose Veldman-Ariesen, . (2011) Absence of Influenza A(H1N1) During Seasonal and Pandemic Seasons in a Sentinel Nursing Home Surveillance Network in the Netherlands. Journal of the American Geriatrics Society 59:12, 2301-2305
CrossRef58
Vladimir Gilca, Gaston De Serres, Marie-Eve Hamelin, Guy Boivin, Manale Ouakki, Nicole Boulianne, Chantal Sauvageau, Marc Dionne, Rodica Gilca, Danuta Skowronski. (2011) Antibody persistence and response to 2010–2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 30:1, 35-41
CrossRef59
A. Steens, S. Waaijenborg, P. F. M. Teunis, J. H. J. Reimerink, A. Meijer, M. van der Lubben, M. Koopmans, M. A. B. van der Sande, J. Wallinga, M. van Boven. (2011) Age-Dependent Patterns of Infection and Severity Explaining the Low Impact of 2009 Influenza A (H1N1): Evidence From Serial Serologic Surveys in the Netherlands. American Journal of Epidemiology 174:11, 1307-1315
CrossRef60
Jeffery K. Taubenberger, John C. Kash. (2011) Insights on influenza pathogenesis from the grave. Virus Research 162:1-2, 2-7
CrossRef61
Massimiliano Fabbiani, Michela Sali, Valentina Di Cristo, Giulia Pignataro, Valentina Prete, Salvatore Farina, Alessandro D'Avino, Stefania Manzara, Lorenzo Zileri dal Verme, Nicolò Gentiloni Silveri, Roberto Cauda, Giovanni Delogu, Giovanni Fadda, Simona Di Giambenedetto. (2011) Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. Journal of Medical Virology 83:12, 2057-2065
CrossRef62
Jenifer L. Jaeger, Minal Patel, Nila Dharan, Kathy Hancock, Elissa Meites, Christine Mattson, Matt Gladden, David Sugerman, Saumil Doshi, Dianna Blau, Kathleen Harriman, Melissa Whaley, Hong Sun, Michele Ginsberg, Annie S. Kao, Paula Kriner, Stephen Lindstrom, Seema Jain, Jacqueline Katz, Lyn Finelli, Sonja J. Olsen, Alexander J. Kallen. (2011) Transmission of 2009 Pandemic Influenza A (H1N1) Virus among Healthcare Personnel—Southern California, 2009. Infection Control and Hospital Epidemiology 32:12, 1149-1157
CrossRef63
Sanford R. Kimmel. (2011) The Course and Management of the 2009 H1N1 Pandemic Influenza. Primary Care: Clinics in Office Practice 38:4, 693-701
CrossRef64
J.H.C.M. Kreijtz, R.A.M. Fouchier, G.F. Rimmelzwaan. (2011) Immune responses to influenza virus infection. Virus Research 162:1-2, 19-30
CrossRef65
Soo Ah Im, Hyo Lim Kim, Jong-seo Yoon, Jin Han Kang, Joon-Sung Lee, Ho Jong Chun. (2011) Swine-origin influenza A viral (H1N1) infection in children: chest computed tomography findings. Japanese Journal of Radiology 29:10, 707-711
CrossRef66
Anita Hansen, Sebastian Grund, Gerd Hetzel, Katrin Ivens, Heike Angela Sümmchen, Panagiota Zgoura, Hartmut Hengel, Ortwin Adams, Lars Christian Rump. (2011) Noncontrolled Trial of Monovalent AS03A-Adjuvanted Vaccine for 2009 Pandemic Influenza A(H1N1) in Long-term Dialysis Patients and Transplant Recipients. American Journal of Kidney Diseases
CrossRef67
M. Koopmans, E. de Bruin, G.-J. Godeke, I. Friesema, R. van Gageldonk, M. Schipper, A. Meijer, R. van Binnendijk, G. F. Rimmelzwaan, M. D. de Jong, A. Buisman, J. van Beek, D. van de Vijver, J. Reimerink. (2011) Profiling of humoral immune responses to influenza viruses by using protein microarray. Clinical Microbiology and Infectionno-no
CrossRef68
Y. Tsuchihashi, T. Sunagawa, Y. Yahata, H. Takahashi, T. Toyokawa, F. Odaira, T. Ohyama, K. Taniguchi, N. Okabe. (2011) Association Between Seasonal Influenza Vaccination in 2008-2009 and Pandemic Influenza A (H1N1) 2009 Infection Among School Students From Kobe, Japan, April-June 2009. Clinical Infectious Diseases
CrossRef69
L. YANG, K. P. CHAN, B. J. COWLING, S. S. CHIU, K. H. CHAN, J. S. M. PEIRIS, C. M. WONG. (2011) Excess mortality associated with the 2009 pandemic of influenza A(H1N1) in Hong Kong. Epidemiology and Infection1-9
CrossRef70
C. Reinheimer, H. W. Doerr, I. Friedrichs, M. Stürmer, R. Allwinn. (2011) H1N1v at a seroepidemiological glance: is the nightmare over?. European Journal of Clinical Microbiology & Infectious Diseases
CrossRef71
C. Qiu, Y. Huang, Q. Wang, D. Tian, W. Zhang, Y. Hu, Z. Yuan, X. Zhang, J. Xu. (2011) Boosting Heterosubtypic Neutralization Antibodies in Recipients of 2009 Pandemic H1N1 Influenza Vaccine. Clinical Infectious Diseases
CrossRef72
Koert J. Stittelaar, Edwin J.B. Veldhuis Kroeze, Larisa Rudenko, Rajeev Dhere, Sit Thirapakpoomanunt, Marie Paule Kieny, Albert D.M.E. Osterhaus. (2011) Efficacy of live attenuated vaccines against 2009 pandemic H1N1 influenza in ferrets. Vaccine 29:49, 9265-9270
CrossRef73
Leticia Elizondo-Montemayor, Mario M. Alvarez, Martín Hernández-Torre, Patricia A. Ugalde-Casas, Lorena Lam-Franco, Humberto Bustamante-Careaga, Fernando Castilleja-Leal, Julio Contreras-Castillo, Héctor Moreno-Sánchez, Daniela Tamargo-Barrera, Felipe López-Pacheco, Pamela J. Freiden, Stacey Schultz-Cherry. (2011) Seroprevalence of antibodies to influenza A/H1N1/2009 among transmission risk groups after the second wave in Mexico, by a virus-free ELISA method. International Journal of Infectious Diseases 15:11, e781-e786
CrossRef74
Kaval Kaur, Meghan Sullivan, Patrick C. Wilson. (2011) Targeting B cell responses in universal influenza vaccine design. Trends in Immunology 32:11, 524-531
CrossRef75
A. Mathian, H. Devilliers, A. Krivine, N. Costedoat-Chalumeau, J. Haroche, D. Boutin-Le Thi Huong, B. Wechsler, B. Hervier, M. Miyara, N. Morel, N. Le Corre, L. Arnaud, J. C. Piette, L. Musset, B. Autran, F. Rozenberg, Z. Amoura. (2011) Factors influencing the efficacy of two injections of a pandemic 2009 influenza A (H1N1) nonadjuvanted vaccine in systemic lupus erythematosus. Arthritis & Rheumatism 63:11, 3502-3511
CrossRef76
Maria E. Lorenzo, Andrea Hodgson, Dionne P. Robinson, Jenifer B. Kaplan, Andrew Pekosz, Sabra L. Klein. (2011) Antibody responses and cross protection against lethal influenza A viruses differ between the sexes in C57BL/6 mice. Vaccine 29:49, 9246-9255
CrossRef77
T. Valente, F. Lassandro, M. Marino, F. Squillante, M. Aliperta, R. Muto. (2011) H1N1 pneumonia: our experience in 50 patients with a severe clinical course of novel swine-origin influenza A (H1N1) virus (S-OIV). La radiologia medica
CrossRef78
Q. Yuan, X.-D. Cheng, B.-C. Yang, Q.-B. Zheng, Y.-X. Chen, Q.-R. Chen, F. Zeng, R. Zhang, S.-X. Ge, X.-K. Hao, H. Chen, J. Zhang, N.-S. Xia. (2011) Differential diagnosis of pandemic (H1N1) 2009 infection by detection of haemagglutinin with an enzyme-linked immunoassay. Clinical Microbiology and Infection 17:10, 1574-1580
CrossRef79
Gillian M. Air, JingQi Feng, Tao Chen, Michelle L. Joachims, Judith A. James, Linda F. Thompson. (2011) Individual Antibody and T Cell Responses to Vaccination and Infection with the 2009 Pandemic Swine-Origin H1N1 Influenza Virus. Journal of Clinical Immunology 31:5, 900-912
CrossRef80
Pieter L.A. Fraaij, Terho Heikkinen. (2011) Seasonal influenza: The burden of disease in children. Vaccine 29:43, 7524-7528
CrossRef81
Day-Yu Chao, Kuang-Fu Cheng, Tsai-Chung Li, Trong-Neng Wu, Chiu-Ying Chen, Chen-An Tsai, Jin-Hua Chen, Hsien-Tsai Chiu, Jang-Jih Lu, Mei-Chi Su, Yu-Hsin Liao, Wei-Cheng Chan, Ying-Hen Hsieh. (2011) Factors associated with infection by 2009 pandemic H1N1 influenza virus during different phases of the epidemic. International Journal of Infectious Diseases 15:10, e695-e701
CrossRef82
Saskia Gueller, Regina Allwinn, Sabine Mousset, Hans Martin, Imke Wieters, Eva Herrmann, Hubert Serve, Markus Bickel, Gesine Bug. (2011) Enhanced Immune Response after a Second Dose of an AS03-Adjuvanted H1N1 Influenza A Vaccine in Patients after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 17:10, 1546-1550
CrossRef83
M. L. B. Hillaire, S. E. van Trierum, J. H. C. M. Kreijtz, R. Bodewes, M. M. Geelhoed-Mieras, N. J. Nieuwkoop, R. A. M. Fouchier, T. Kuiken, A. D. M. E. Osterhaus, G. F. Rimmelzwaan. (2011) Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. Journal of General Virology 92:10, 2339-2349
CrossRef84
Cory Simon, Niño Yosinao. (2011) A mathematical model to distinguish sociological and biological susceptibility factors in disease transmission in the context of H1N1/09 influenza. Journal of Theoretical Biology 286, 50-56
CrossRef85
Takao Toyokawa, Tomimasa Sunagawa, Yuichiro Yahata, Takaaki Ohyama, Tomoko Kodama, Hiroshi Satoh, Kumi Ueno-Yamamoto, Satoru Arai, Kazuko Araki, Fumito Odaira, Yuuki Tsuchihashi, Hideaki Takahashi, Keiko Tanaka-Taya, Nobuhiko Okabe. (2011) Seroprevalence of antibodies to pandemic (H1N1) 2009 influenza virus among health care workers in two general hospitals after first outbreak in Kobe, Japan. Journal of Infection 63:4, 281-287
CrossRef86
E. Cordero, A. Perez-Ordoñez, T. A. Aydillo, J. Torre-Cisneros, J. Gavalda, R. Lara, C. Segura, O. Len, E. Cabral, A. Gasch, J. Pachon, P. Perez-Romero. (2011) Therapy With m-TOR Inhibitors Decreases the Response to the Pandemic Influenza A H1N1 Vaccine in Solid Organ Transplant Recipients. American Journal of Transplantation 11:10, 2205-2213
CrossRef87
X. WANG, X. W. CHENG, H. W. MA, J. F. HE, X. XIE, S. S. FANG, C. L. WU, X. LU, S. J. MEI, Y. LI, J. Q. CHENG. (2011) Influenza surveillance in Shenzhen, the largest migratory metropolitan city of China, 2006–2009. Epidemiology and Infection 139:10, 1551-1559
CrossRef88
Pieter LA Fraaij, Rogier Bodewes, Albert DME Osterhaus, Guus F Rimmelzwaan. (2011) The ins and outs of universal childhood influenza vaccination. Future Microbiology 6:10, 1171-1184
CrossRef89
Fuyan Sun, Yunzhi Zhang, Di Tian, Min Zheng, Li Liu, Renfang Zhang, Zhengsheng Dai, Jun Chen, Tingting Li, Hongzhou Lu. (2011) Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population—A practical observation. Vaccine 29:38, 6527-6531
CrossRef90
Swati Kumar, Jiang Fan, Marlene Melzer-Lange, Jessica Trost, Peter L. Havens, Rodney E. Willoughby, Michael J. Chusid, Kelly J. Henrickson. (2011) H1N1 Hemagglutinin-Inhibition Seroprevalence in Emergency Department Health Care Workers After the First Wave of the 2009 Influenza Pandemic. Pediatric Emergency Care 27:9, 804-807
CrossRef91
Michael A. Jhung, Heidi Davidson, Anne McIntyre, William J. Gregg, Sharoda Dasgupta, Tiffany D’Mello, Victoria White, Ashley Fowlkes, Lynnette Brammer, Lyn Finelli. (2011) Preliminary results of 2009 pandemic influenza surveillance in the United States using the Aggregate Hospitalization and Death Reporting Activity. Influenza and Other Respiratory Viruses 5:5, 321-327
CrossRef92
Neven Papic, Ana Pangercic, Martina Vargovic, Bruno Barsic, Adriana Vince, Ilija Kuzman. (2011) Liver involvement during influenza infection: perspective on the 2009 influenza pandemic. Influenza and Other Respiratory Virusesno-no
CrossRef93
J. R. R. Whittle, R. Zhang, S. Khurana, L. R. King, J. Manischewitz, H. Golding, P. R. Dormitzer, B. F. Haynes, E. B. Walter, M. A. Moody, T. B. Kepler, H.-X. Liao, S. C. Harrison. (2011) Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proceedings of the National Academy of Sciences 108:34, 14216-14221
CrossRef94
Yoichi Furuya. (2011) Return of inactivated whole-virus vaccine for superior efficacy. Immunology and Cell Biology
CrossRef95
V. J. Lee, M. I. Chen, J. Yap, J. Ong, W.-Y. Lim, R. T. P. Lin, I. Barr, J. B. S. Ong, T. M. Mak, L. G. Goh, Y. S. Leo, P. M. Kelly, A. R. Cook. (2011) Comparability of Different Methods for Estimating Influenza Infection Rates Over a Single Epidemic Wave. American Journal of Epidemiology 174:4, 468-478
CrossRef96
Heath A. Kelly, Kristina A. Grant, James E. Fielding, Kylie S. Carville, Clare O. Looker, Thomas Tran, Peter Jacoby. (2011) Pandemic influenza H1N1 2009 infection in Victoria, Australia: No evidence for harm or benefit following receipt of seasonal influenza vaccine in 2009. Vaccine 29:37, 6419-6426
CrossRef97
M. Coppola, A. Porto, D. Santo, S. Fronzo, R. Grassi, A. Rotondo. (2011) Influenza A virus: radiological and clinical findings of patients hospitalised for pandemic H1N1 influenza. La radiologia medica 116:5, 706-719
CrossRef98
W. Poeppl, M. Hell, H. Herkner, B. Stoiser, G. Fritsche, N. Schurz-Bamieh, G. Poeppl, R. Gattringer, N. Jones, M. Maass, A. Egle, H. Burgmann. (2011) Clinical aspects of 2009 pandemic influenza A (H1N1) virus infection in Austria. Infection 39:4, 341-352
CrossRef99
J. Kevin Yin, Han Wang, S. Rachel Skinner, Glenn Salkeld, Robert Booy. (2011) Assessing seasonal vaccine-related cross-protection from 2009 pandemic H1N1 influenza through teacher absenteeism. Australian and New Zealand Journal of Public Health 35:4, 393-394
CrossRef100
Sanae Sasaki, Meghan Sullivan, Carlos F. Narvaez, Tyson H. Holmes, David Furman, Nai-Ying Zheng, Madhuri Nishtala, Jens Wrammert, Kenneth Smith, Judith A. James, Cornelia L. Dekker, Mark M. Davis, Patrick C. Wilson, Harry B. Greenberg, Xiao-Song He. (2011) Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. Journal of Clinical Investigation 121:8, 3109-3119
CrossRef101
Y. Zhou, D.M.W. Ng, W.-H. Seto, D.K.M. Ip, H.K.H. Kwok, E.S.K. Ma, S. Ng, L.L.H. Lau, J.T. Wu, J.S.M. Peiris, B.J. Cowling. (2011) Seroprevalence of antibody to pandemic influenza A (H1N1) 2009 among healthcare workers after the first wave in Hong Kong. Journal of Hospital Infection 78:4, 308-311
CrossRef102
J. K. Taubenberger, D. M. Morens, R. M. Krause, A. S. Fauci. (2011) In Memoriam: Edwin D. Kilbourne, MD, 1920-2011. Journal of Infectious Diseases 204:2, 185-187
CrossRef103
Rafael A. Medina, Adolfo García-Sastre. (2011) Influenza A viruses: new research developments. Nature Reviews Microbiology 9:8, 590-603
CrossRef104
W. Tu, J. Zheng, Y. Liu, S. F. Sia, M. Liu, G. Qin, I. H. Y. Ng, Z. Xiang, K.-T. Lam, J. S. M. Peiris, Y.-L. Lau. (2011) The aminobisphosphonate pamidronate controls influenza pathogenesis by expanding a T cell population in humanized mice. Journal of Experimental Medicine 208:7, 1511-1522
CrossRef105
Y. Chen, Q. Zheng, K. Yang, F. Zeng, S.-Y. Lau, W. L. Wu, S. Huang, J. Zhang, H. Chen, N. Xia. (2011) Serological survey of antibodies to influenza A viruses in a group of people without a history of influenza vaccination. Clinical Microbiology and Infectionno-no
CrossRef106
Kanwal Kumar, Mina Guirgis, Shelley Zieroth, Evelyn Lo, Alan H. Menkis, Rakesh C. Arora, Darren H. Freed. (2011) Influenza Myocarditis and Myositis: Case Presentation and Review of the Literature. Canadian Journal of Cardiology 27:4, 514-522
CrossRef107
Mary C. Christman, Ambreen Kedwaii, Jianpeng Xu, Ruben O. Donis, Guoqing Lu. (2011) Pandemic (H1N1) 2009 virus revisited: An evolutionary retrospective. Infection, Genetics and Evolution 11:5, 803-811
CrossRef108
Peter Doshi. (2011) The elusive definition of pandemic influenza. Bulletin of the World Health Organization 89:7, 532-538
CrossRef109
Angelina Noviani Lee, Yossa Dwi Hartono, Tiedong Sun, Min Li Leow, Xue-wei Liu, Xuri Huang, Dawei Zhang. (2011) Molecular dynamics studies of human receptor molecule in hemagglutinin of 1918 and 2009 H1N1 influenza viruses. Journal of Molecular Modeling 17:7, 1635-1641
CrossRef110
Garry W Lynch, Paul Selleck, W Bret Church, John S Sullivan. (2011) Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans. Immunology and Cell Biology
CrossRef111
G. Katriel, R. Yaari, A. Huppert, U. Roll, L. Stone. (2011) Modelling the initial phase of an epidemic using incidence and infection network data: 2009 H1N1 pandemic in Israel as a case study. Journal of The Royal Society Interface 8:59, 856-867
CrossRef112
S. Esposito, E. Meregalli, C. Daleno, L. Ghio, C. Tagliabue, A. Valzano, D. Serra, C. Galeone, A. Edefonti, N. Principi. (2011) An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrology Dialysis Transplantation 26:6, 2018-2024
CrossRef113
Jen Kok, Dominic E Dwyer. (2011) How common was 2009 pandemic influenza A H1N1?. The Lancet Infectious Diseases 11:6, 423-424
CrossRef114
David M. Morens, Jeffery K. Taubenberger. (2011) Pandemic influenza: certain uncertainties. Reviews in Medical Virologyn/a-n/a
CrossRef115
E. C. Settembre, P. R. Dormitzer, R. Rappuoli. (2011) Learning from the 2009 H1N1 pandemic: prospects for more broadly effective influenza vaccines. Journal of Molecular Cell Biology 3:3, 144-146
CrossRef116
Koji Takayama, Jin Kuramochi, Takeshi Oinuma, Hiromi Kaneko, Satoshi Kurasawa, Makito Yasui, Kaori Okayasu, Hiroshi Ono, Naohiko Inase. (2011) Clinical features of the 2009 swine-origin influenza A (H1N1) outbreak in Japan. Journal of Infection and Chemotherapy 17:3, 401-406
CrossRef117
J. Garcia-Sicilia, P. Gillard, A. Carmona, J.C. Tejedor, J. Aristegui, J.M. Merino, U. Behre, A. Caplanusi, T. Vaman, I. Dieussaert. (2011) Immunogenicity and safety of AS03-adjuvanted H1N1 pandemic vaccines in children and adolescents. Vaccine 29:26, 4353-4361
CrossRef118
Maria D. Mavrouli, John G. Routsias, Helena C. Maltezou, Nicholas Spanakis, Athanassios Tsakris. (2011) Estimation of Seroprevalence of the Pandemic H1N1 2009 Influenza Virus Using a Novel Virus-Free ELISA Assay for the Detection of Specific Antibodies. Viral Immunology 24:3, 221-226
CrossRef119
S. Boxhammer, R. Lepler, H. Lenhartz, B. Püst, P.H. Höger. (2011) Influenza A/H1N1-2009 bei Kindern und Jugendlichen in Hamburg. Monatsschrift Kinderheilkunde 159:6, 560-564
CrossRef120
Chang-Zheng DONG. (2011) Advances on genomic evolution of influenza virus. Hereditas (Beijing) 33:3, 189-197
CrossRef121
Shoji Kawachi, Takeji Matsushita, Takeyuki Sato, Hiroyuki Nunoi, Hiroshi Noguchi, Setsuo Ota, Nobuko Kanemoto, Keigo Nakatani, Toshihiro Nishiguchi, Akihiko Yuge, Hideaki Imamura, Hirotake Kitajima, Kenji Narahara, Kazuo Suzuki, Tohru Miyoshi-Akiyama, Teruo Kirikae. (2011) Multicenter prospective evaluation of a novel rapid immunochromatographic diagnostic kit specifically detecting influenza A H1N1 2009 virus. Journal of Clinical Virology 51:1, 68-72
CrossRef122
C. Weil Olivier. (2011) Vaccins contre la grippe, durée de l’immunité. Archives de Pédiatrie 18:5, H164-H165
CrossRef123
Paula Garland, Hugues de Lavallade, Takuya Sekine, Katja Hoschler, Shiranee Sriskandan, Parind Patel, Stephen Brett, Kate Stringaris, Eva Loucaides, Katherine Howe, David Marin, Ed Kanfer, Nichola Cooper, Donald Macdonald, Amin Rahemtulla, Mark Atkins, Akila Danga, Dragana Milojkovic, Ian Gabriel, Ahmad Khoder, Abdullah Alsuliman, Jane Apperley, Katayoun Rezvani. (2011) Humoral and Cellular Immunity to Primary H1N1 Infection in Patients with Hematologic Malignancies following Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 17:5, 632-639
CrossRef124
, A. Mercat, T. Pham, H. Rozé, E. Cuquemelle, C. Brun-Buisson, L. Brochard, J. -C. -M. Richard. (2011) Formes graves de la grippe H1N1 2009 chez l’adulte: l’expérience française. Réanimation 20:3, 162-168
CrossRef125
Judith D. Easterbrook, John C. Kash, Zong-Mei Sheng, Li Qi, Jin Gao, Edwin D. Kilbourne, Maryna C. Eichelberger, Jeffery K. Taubenberger. (2011) Immunization with 1976 swine H1N1- or 2009 pandemic H1N1-inactivated vaccines protects mice from a lethal 1918 influenza infection. Influenza and Other Respiratory Viruses 5:3, 198-205
CrossRef126
Ralf Dikow, Isabella Eckerle, Dorothea Ksoll-Rudek, Heidrun Hampel, Vedat Schwenger, Martin Zeier, Paul Schnitzler, Claudia Sommerer. (2011) Immunogenicity and Efficacy in Hemodialysis Patients of an AS03A-Adjuvanted Vaccine for 2009 Pandemic Influenza A(H1N1): A Nonrandomized Trial. American Journal of Kidney Diseases 57:5, 716-723
CrossRef127
M. Lemaitre, M. Leruez-Ville, X. N. De Lamballerie, N. Salez, P. Garrone, A.-C. Fluckiger, D. Klatzmann, F. Carrat. (2011) Seasonal H1N1 2007 influenza virus infection is associated with elevated pre-exposure antibody titers to the 2009 pandemic influenza A (H1N1) virus. Clinical Microbiology and Infection 17:5, 732-737
CrossRef128
Gabriele Neumann, Yoshihiro Kawaoka. (2011) The first influenza pandemic of the new millennium. Influenza and Other Respiratory Viruses 5:3, 157-166
CrossRef129
K. Kelen, D. Ferenczi, I. Jankovics, M. Varga, M.Z. Molnar, P. Sallay, G. Reusz, R.M. Langer, K. Pasti, Z. Gerlei, A.J. Szabo. (2011) H1N1 Vaccination in Pediatric Renal Transplant Patients. Transplantation Proceedings 43:4, 1244-1246
CrossRef130
Wilfred Ndifon. (2011) New methods for analyzing serological data with applications to influenza surveillance. Influenza and Other Respiratory Viruses 5:3, 206-212
CrossRef131
Gulam Khandaker, Alexa Dierig, Harunor Rashid, Catherine King, Leon Heron, Robert Booy. (2011) Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza and Other Respiratory Viruses 5:3, 148-156
CrossRef132
Jing Fang, Zhihui Chen, Xiaoqing Liu, Huaifang Li, Jianjun Wang, Xiaona Shen, Wei Chen, Yuan Liu, Yue Wang, Ping Zhao, Zhongtian Qi. (2011) Immunization with a low dose of hemagglutinin-encoding plasmid protects against 2009 H1N1 pandemic influenza virus in mice. Journal of Virological Methods 173:2, 314-319
CrossRef133
Sophia Tan, David L. Gordon, Yoshikazu Honda-Okubo, Nikolai Petrovsky, Peter Phillips, Sandra Huddleston, Tania A. Sadlon. (2011) Serological responses following influenza A H1N1 2009 infection in adults. Journal of Infection 62:5, 388-393
CrossRef134
Massimiliano Fabbiani, Simona Di Giambenedetto, Michela Sali, Salvatore Farina, Paola Sansonetti, Enrica Tamburrini, Lorenzo Zileri Dal Verme, Giovanni Delogu, Andrea De Luca, David Kelvin, Roberto Cauda, Giovanni Fadda. (2011) Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. Vaccine 29:16, 2836-2839
CrossRef135
Kristen C. Sihler, Pauline K. Park. (2011) Extracorporeal Membrane Oxygenation in the Context of the 2009 H1N1 Influenza A Pandemic. Surgical Infections 12:2, 151-158
CrossRef136
Jenish R. Patel, Keyur P. Vora, Shashank Tripathi, Hui Zeng, Terrence M. Tumpey, Jacqueline M. Katz, Suryaprakash Sambhara, Shivaprakash Gangappa. (2011) Infection of Lung Epithelial Cells with Pandemic 2009 A(H1N1) Influenza Viruses Reveals Isolate-Specific Differences in Infectivity and Host Cellular Responses. Viral Immunology 24:2, 89-99
CrossRef137
C. Reinheimer, R. Allwinn, H. W. Doerr. (2011) Limited prevalence of influenza A/H1N1v antibodies: footprints of the pandemic of 2010. Infection 39:2, 101-104
CrossRef138
S. Giambenedetto, L. Zileri Dal Verme, M. Sali, S. Farina, V. Cristo, S. Manzara, A. Luca, G. Pignataro, M. Prosperi, A. Franco, N. Gentiloni Silveri, G. Delogu, R. Cauda, M. Fabbiani, G. Fadda. (2011) Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. European Journal of Clinical Microbiology & Infectious Diseases 30:4, 541-549
CrossRef139
Brian C. Schanen, Anne S. De Groot, L. Moise, Matt Ardito, Elizabeth McClaine, William Martin, Vaughan Wittman, William L. Warren, Donald R. Drake. (2011) Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virus. Vaccine 29:17, 3299-3309
CrossRef140
Dhanraj Samuel, Lenesha Warrener, Katja Hoschler. (2011) Monoclonal antibodies to the haemagglutinin HA1 subunit of the pandemic influenza A/H1N1 2009 virus and potential application to serodiagnosis. Journal of Medical Virology 83:4, 559-567
CrossRef141
G. L. Chen, J.-Y. Min, E. W. Lamirande, C. Santos, H. Jin, G. Kemble, K. Subbarao. (2011) Comparison of a Live Attenuated 2009 H1N1 Vaccine with Seasonal Influenza Vaccines against 2009 Pandemic H1N1 Virus Infection in Mice and Ferrets. Journal of Infectious Diseases 203:7, 930-936
CrossRef142
Melissa B. Pearce, Jessica A. Belser, Katherine V. Houser, Jacqueline M. Katz, Terrence M. Tumpey. (2011) Efficacy of seasonal live attenuated influenza vaccine against virus replication and transmission of a pandemic 2009 H1N1 virus in ferrets. Vaccine 29:16, 2887-2894
CrossRef143
L. Labriola, A. Hombrouck, C. Marechal, S. Van Gucht, B. Brochier, I. Thomas, M. Jadoul, P. Goubau. (2011) Immunogenicity of an adjuvanted 2009 pandemic influenza A (H1N1) vaccine in haemodialysed patients. Nephrology Dialysis Transplantation 26:4, 1424-1428
CrossRef144
Nancy F. Crum-Cianflone, Erik Iverson, Gabriel Defang, Patrick J. Blair, Lynn E. Eberly, Jason Maguire, Anuradha Ganesan, Dennis Faix, Christopher Duplessis, Tahaniyat Lalani, Timothy Whitman, Carolyn Brandt, Grace Macalino, Eugene V. Millar, Timothy Burgess. (2011) Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults. Vaccine 29:17, 3183-3191
CrossRef145
(2011) Safety and Effectiveness of a 2009 H1N1 Vaccine in Beijing. New England Journal of Medicine 364:12, 1181-1182
Full Text146
Benoît Baras, Leon de Waal, Koert J. Stittelaar, Valérie Jacob, Sandra Giannini, Edwin J.B. Veldhuis Kroeze, Judith M.A. van den Brand, Geert van Amerongen, James H. Simon, Emmanuel Hanon, Sally P. Mossman, Albert D.M.E. Osterhaus. (2011) Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets. Vaccine 29:11, 2120-2126
CrossRef147
Ruiqi Zhang, Xia Rong, Weiqi Pan, Tao Peng. (2011) Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1. Scandinavian Journal of Infectious Diseases 43:3, 216-220
CrossRef148
Nicolas C. Issa, Francisco M. Marty, Lisa S. Gagne, Sophia Koo, Kelly A. Verrill, Edwin P. Alyea, Corey S. Cutler, John Koreth, Philippe Armand, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Lindsey R. Baden. (2011) Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation 17:3, 434-438
CrossRef149
Svenn-Erik Mamelund. (2011) Geography May Explain Adult Mortality from the 1918–20 Influenza Pandemic. Epidemics 3:1, 46-60
CrossRef150
Kristin Scheible, Gang Zhang, Jane Baer, Mitra Azadniv, Kris Lambert, Gloria Pryhuber, John J. Treanor, David J. Topham. (2011) CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses. Vaccine 29:11, 2159-2168
CrossRef151
Antoine Nougairède, Rémi N. Charrel, Didier Raoult. (2011) Models cannot predict future outbreaks: A/H1N1 virus, the paradigm. European Journal of Epidemiology 26:3, 183-186
CrossRef152
Dabin Liu, Bingyin Si, Cun Li, Zhiqiang Mi, Xiaoping An, Chengfeng Qin, Wei Liu, Yigang Tong. (2011) Prokaryotic expression and purification of HA1 and HA2 polypeptides for serological analysis of the 2009 pandemic H1N1 influenza virus. Journal of Virological Methods 172:1-2, 16-21
CrossRef153
I. F. Hung, K. K. To, C.-K. Lee, K.-L. Lee, K. Chan, W.-W. Yan, R. Liu, C.-L. Watt, W.-M. Chan, K.-Y. Lai, C.-K. Koo, T. Buckley, F.-L. Chow, K.-K. Wong, H.-S. Chan, C.-K. Ching, B. S. Tang, C. C. Lau, I. W. Li, S.-H. Liu, K.-H. Chan, C.-K. Lin, K.-Y. Yuen. (2011) Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clinical Infectious Diseases 52:4, 447-456
CrossRef154
Karl G Nicholson, Keith R Abrams, Sally Batham, Tristan W Clark, Katja Hoschler, Wei Shen Lim, Marie-Jo Medina, Jonathan S Nguyen-Van-Tam, Robert C Read, Fiona C Warren, Maria Zambon. (2011) Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. The Lancet Infectious Diseases 11:2, 91-101
CrossRef155
Susanna Esposito, Laura Tagliaferri, Cristina Daleno, Antonia Valzano, Irene Picciolli, Francesca Tel, Giulia Prunotto, Domenico Serra, Carlotta Galeone, Anna Plebani, Nicola Principi. (2011) Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 29:8, 1677-1682
CrossRef156
Jen Kok, Katherine Tudo, Christopher C Blyth, Hong Foo, Linda Hueston, Dominic E Dwyer. (2011) Pandemic (H1N1) 2009 Influenza Virus Seroconversion Rates in HIV-Infected Individuals. JAIDS Journal of Acquired Immune Deficiency Syndromes 56:2, 91-94
CrossRef157
Ricardo Rabagliati, Jaime Labarca, Leonardo Siri, Carlos M. Perez, Marcela Ferrés. (2011) Rates of Hospital-Acquired Influenza Due to the Pandemic H1N1 Virus in 2009, Compared with Seasonal Influenza. Infection Control and Hospital Epidemiology 32:2, 198-200
CrossRef158
Jiu Jiang, Erin M. Fisher, Donna M. Murasko. (2011) CD8 T cell responses to influenza virus infection in aged mice. Ageing Research Reviews
CrossRef159
S. Grund, O. Adams, S. Wählisch, B. Schweiger. (2011) Comparison of hemagglutination inhibition assay, an ELISA-based micro-neutralization assay and colorimetric microneutralization assay to detect antibody responses to vaccination against influenza A H1N1 2009 virus. Journal of Virological Methods 171:2, 369-373
CrossRef160
M. Loebermann, G. Anders, G. Brestrich, C. Fritzsche, S. Klammt, D. Boršo, S. Frimmel, D. Riebold, E.C. Reisinger. (2011) Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: A phase III open-label single-arm study. Vaccine 29:6, 1228-1234
CrossRef161
Ana Clara Monsalvo, Juan P Batalle, M Florencia Lopez, Jens C Krause, Jennifer Klemenc, Johanna Zea Hernandez, Bernardo Maskin, Jimena Bugna, Carlos Rubinstein, Leandro Aguilar, Liliana Dalurzo, Romina Libster, Vilma Savy, Elsa Baumeister, Liliana Aguilar, Graciela Cabral, Julia Font, Liliana Solari, Kevin P Weller, Joyce Johnson, Marcela Echavarria, Kathryn M Edwards, James D Chappell, James E Crowe, John V Williams, Guillermina A Melendi, Fernando P Polack. (2011) Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nature Medicine 17:2, 195-199
CrossRef162
Dan Engelhard, Zichria Zakay-Rones, Michael Y. Shapira, Igor Resnick, Diana Averbuch, Sigal Grisariu, Lillian Dray, Esther Djian, Nurith Strauss-Liviatan, Itamar Grotto, Dana G. Wolf, Reuven Or. (2011) The humoral immune response of hematopoietic stem cell transplantation recipients to AS03-adjuvanted A/California/7/2009 (H1N1)v-like virus vaccine during the 2009 pandemic. Vaccine 29:9, 1777-1782
CrossRef163
Joon Young Song, Hee Jin Cheong, Jung Yeon Heo, Ji Yun Noh, Won Suk Choi, Dae Won Park, Jacob Lee, Hye Won Jeong, Sae Yoon Kee, Woo Joo Kim. (2011) Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 29:7, 1395-1398
CrossRef164
H. Seale, R. Kaur, Q. Wang, P. Yang, Y. Zhang, X. Wang, X. Li, H. Zhang, Z. Zhang, C.R. MacIntyre. (2011) Acceptance of a vaccine against pandemic influenza A (H1N1) virus amongst healthcare workers in Beijing, China. Vaccine 29:8, 1605-1610
CrossRef165
G. L. Chen, Y.-F. Lau, E. W. Lamirande, A. W. McCall, K. Subbarao. (2011) Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine. Proceedings of the National Academy of Sciences 108:3, 1140-1145
CrossRef166
J. Wrammert, D. Koutsonanos, G.-M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. Skountzou, M. Hornig, W. I. Lipkin, A. Mehta, B. Razavi, C. Del Rio, N.-Y. Zheng, J.-H. Lee, M. Huang, Z. Ali, K. Kaur, S. Andrews, R. R. Amara, Y. Wang, S. R. Das, C. D. O'Donnell, J. W. Yewdell, K. Subbarao, W. A. Marasco, M. J. Mulligan, R. Compans, R. Ahmed, P. C. Wilson. (2011) Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. Journal of Experimental Medicine 208:1, 181-193
CrossRef167
O. Manuel, M. Pascual, K. Hoschler, S. Giulieri, D. Alves, K. Ellefsen, P.-A. Bart, J.-P. Venetz, T. Calandra, M. Cavassini. (2011) Humoral Response to the Influenza A H1N1/09 Monovalent AS03-Adjuvanted Vaccine in Immunocompromised Patients. Clinical Infectious Diseases 52:2, 248-256
CrossRef168
D. M. Skowronski, T. S. Hottes, J. E. McElhaney, N. Z. Janjua, S. Sabaiduc, T. Chan, B. Gentleman, D. Purych, J. Gardy, D. M. Patrick, R. C. Brunham, G. De Serres, M. Petric. (2011) Immuno-epidemiologic Correlates of Pandemic H1N1 Surveillance Observations: Higher Antibody and Lower Cell-Mediated Immune Responses with Advanced Age. Journal of Infectious Diseases 203:2, 158-167
CrossRef169
J. Shaman, E. Goldstein, M. Lipsitch. (2011) Absolute Humidity and Pandemic Versus Epidemic Influenza. American Journal of Epidemiology 173:2, 127-135
CrossRef170
Gergely Röst, Diána Knipl. (2011) Modelling the strategies for age specific vaccination scheduling during influenza pandemic outbreaks. Mathematical Biosciences and Engineering 8:1, 123-139
CrossRef171
A. L. Fowlkes, P. Arguin, M. S. Biggerstaff, J. Gindler, D. Blau, S. Jain, R. Dhara, J. McLaughlin, E. Turnipseed, J. J. Meyer, J. K. Louie, A. Siniscalchi, J. J. Hamilton, A. Reeves, S. Y. Park, D. Richter, M. D. Ritchey, N. M. Cocoros, D. Blythe, S. Peters, R. Lynfield, L. Peterson, J. Anderson, Z. Moore, R. Williams, L. McHugh, C. Cruz, C. L. Waters, S. L. Page, C. K. McDonald, M. Vandermeer, K. Waller, U. Bandy, T. F. Jones, L. Bullion, V. Vernon, K. H. Lofy, T. Haupt, L. Finelli. (2011) Epidemiology of 2009 Pandemic Influenza A (H1N1) Deaths in the United States, April-July 2009. Clinical Infectious Diseases 52:Supplement 1, S60-S68
CrossRef172
J. Skarbinski, S. Jain, A. Bramley, E. J. Lee, J. Huang, D. Kirschke, A. Stone, T. Wedlake, S. M. Richards, S. Page, P. Ragan, L. Bullion, D. Neises, R. M. Williams, B. P. Petruccelli, M. Vandermeer, K. H. Lofy, J. Gindler, L. Finelli, . (2011) Hospitalized Patients with 2009 Pandemic Influenza A (H1N1) Virus Infection in the United States--September-October 2009. Clinical Infectious Diseases 52:Supplement 1, S50-S59
CrossRef173
Diego López Mendoza, Marcos I. Restrepo. (2011) Severe pandemic H1N1 2009 influenza A infection: Are we ready to move on?. Respirology 16:1, 1-2
CrossRef174
S. E. Forgie, J. Keenliside, C. Wilkinson, R. Webby, P. Lu, O. Sorensen, K. Fonseca, S. Barman, A. Rubrum, E. Stigger, T. J. Marrie, F. Marshall, D. W. Spady, J. Hu, M. Loeb, M. L. Russell, L. A. Babiuk. (2011) Swine Outbreak of Pandemic Influenza A Virus on a Canadian Research Farm Supports Human-to-Swine Transmission. Clinical Infectious Diseases 52:1, 10-18
CrossRef175
Bilgin Arda, Raika Durusoy, Tansu Yamazhan, Oğuz Sipahi, Meltem Taşbakan, Hüsnü Pullukçu, Esra Erdem, Sercan Ulusoy. (2011) Did the pandemic have an impact on influenza vaccination attitude? a survey among health care workers. BMC Infectious Diseases 11:1, 87
CrossRef176
Jodie McVernon, Karen Laurie, Ian Barr, Anne Kelso, Maryanne Skeljo, Terry Nolan. (2011) Absence of cross-reactive antibodies to influenza A (H1N1) 2009 before and after vaccination with 2009 Southern Hemisphere seasonal trivalent influenza vaccine in children aged 6 months-9 years: a prospective study. Influenza and Other Respiratory Viruses 5:1, 7-11
CrossRef177
M. A. Jhung, D. Swerdlow, S. J. Olsen, D. Jernigan, M. Biggerstaff, L. Kamimoto, K. Kniss, C. Reed, A. Fry, L. Brammer, J. Gindler, W. J. Gregg, J. Bresee, L. Finelli. (2011) Epidemiology of 2009 Pandemic Influenza A (H1N1) in the United States. Clinical Infectious Diseases 52:Supplement 1, S13-S26
CrossRef178
Philip R. Dormitzer, Grazia Galli, Flora Castellino, Hana Golding, Surender Khurana, Giuseppe Del Giudice, Rino Rappuoli. (2011) Influenza vaccine immunology. Immunological Reviews 239:1, 167-177
CrossRef179
L. Brammer, L. Blanton, S. Epperson, D. Mustaquim, A. Bishop, K. Kniss, R. Dhara, M. Nowell, L. Kamimoto, L. Finelli. (2011) Surveillance for Influenza during the 2009 Influenza A (H1N1) Pandemic-United States, April 2009-March 2010. Clinical Infectious Diseases 52:Supplement 1, S27-S35
CrossRef180
Robin M. Bush. 2011. Influenza Forensics. , 109-725.
CrossRef181
S. S. Shrestha, D. L. Swerdlow, R. H. Borse, V. S. Prabhu, L. Finelli, C. Y. Atkins, K. Owusu-Edusei, B. Bell, P. S. Mead, M. Biggerstaff, L. Brammer, H. Davidson, D. Jernigan, M. A. Jhung, L. A. Kamimoto, T. L. Merlin, M. Nowell, S. C. Redd, C. Reed, A. Schuchat, M. I. Meltzer. (2011) Estimating the Burden of 2009 Pandemic Influenza A (H1N1) in the United States (April 2009-April 2010). Clinical Infectious Diseases 52:Supplement 1, S75-S82
CrossRef182
K. B. Janusz, J. E. Cortes, F. Serdarevic, R. C. Jones, J. D. Jones, K. A. Ritger, J. Y. Morita, S. I. Gerber, L. Gallagher, B. J. Biggerstaff, L. A. Hicks, D. L. Swerdlow, M. Fischer, J. E. Staples, . (2011) Influenza-Like Illness in a Community Surrounding a School-Based Outbreak of 2009 Pandemic Influenza A (H1N1) Virus-Chicago, Illinois, 2009. Clinical Infectious Diseases 52:Supplement 1, S94-S101
CrossRef183
Ayesha Mirza, Mobeen H. Rathore. (2011) Immunization Update III. Advances in Pediatrics 58:1, 41-64
CrossRef184
Anna Kajaste-Rudnitski, Laura Galli, Silvia Nozza, Giuseppe Tambussi, Andrea Di Pietro, Gabriele Pellicciotta, Alessandro Monti, Paolo Mascagni, Matteo Moro, Elisa Vicenzi. (2011) Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 25:2, 177-183
CrossRef185
N. F. Crum-Cianflone, L. E. Eberly, C. Duplessis, J. Maguire, A. Ganesan, D. Faix, G. Defang, Y. Bai, E. Iverson, T. Lalani, T. Whitman, P. J. Blair, C. Brandt, G. Macalino, T. Burgess. (2011) Immunogenicity of a Monovalent 2009 Influenza A (H1N1) Vaccine in an Immunocompromised Population: A Prospective Study Comparing HIV-Infected Adults with HIV-Uninfected Adults. Clinical Infectious Diseases 52:1, 138-146
CrossRef186
A. Schuchat, B. P. Bell, S. C. Redd. (2011) The Science behind Preparing and Responding to Pandemic Influenza: The Lessons and Limits of Science. Clinical Infectious Diseases 52:Supplement 1, S8-S12
CrossRef187
D. L. Swerdlow, L. Finelli, C. B. Bridges. (2011) 2009 H1N1 Influenza Pandemic: Field and Epidemiologic Investigations in the United States at the Start of the First Pandemic of the 21st Century. Clinical Infectious Diseases 52:Supplement 1, S1-S3
CrossRef188
M. E. FALAGAS, P. K. KOLETSI, E. BASKOUTA, P. I. RAFAILIDIS, G. DIMOPOULOS, D. E. KARAGEORGOPOULOS. (2011) Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience. Epidemiology and Infection 139:01, 27-40
CrossRef189
Sophia Ng, Peng Wu, Hiroshi Nishiura, Dennis KM Ip, Esther ST Lee, Benjamin J Cowling. (2011) An analysis of national target groups for monovalent 2009 pandemic influenza vaccine and trivalent seasonal influenza vaccines in 2009-10 and 2010-11. BMC Infectious Diseases 11:1, 230
CrossRef190
Day-Yu Chao, Kuang-Fu Cheng, Ying-Hen Hsieh, Tsai-Chung Li, Trong-Neng Wu, Chiu-Ying Chen, Chen-An Tsai, Jin-Hwa Chen, Hsien-Tsai Chiu, Jang-Jih Lu, Mei-Chi Su, Yu-Hsin Liao. (2011) Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine. Vaccine 29:4, 617-623
CrossRef191
David K. Hong, Adriana H. Tremoulet, Jane C. Burns, David B. Lewis. (2011) CROSS-REACTIVE NEUTRALIZING ANTIBODY AGAINST PANDEMIC 2009 H1N1 INFLUENZA A VIRUS IN INTRAVENOUS IMMUNOGLOBULIN PREPARATIONS. The Pediatric Infectious Disease Journal 30:1, 67-69
CrossRef192
A.M. Iorio, B. Camilloni, E. Lepri, M. Neri, M. Basileo, A. Azzi. (2011) Induction of Cross-Reactive Antibodies to 2009 Pandemic H1N1 Influenza Virus (pH1N1) After Seasonal Vaccination (Winters 2003/04 and 2007/08). Procedia in Vaccinology 4, 50-58
CrossRef193
Jodie McVernon, Terry Nolan. (2011) Panvax ® : a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009. Expert Review of Vaccines 10:1, 35-43
CrossRef194
So-Yun Nah, Ji Taek Hong, Jae Hyoung Im, Jung Hwan Lee, Areum Durey, Mijeong Kim, Hye-Jin Lee, Shin-Ku Park, Moon-Hyun Chung, Ji Hyeon Baek, Jin-Soo Lee. (2011) Variations in Number of Hospitalized Patients with Cardiopulmonary Diseases Associated with 2009 H1N1 Pandemic Influenza in a Tertiary Teaching Hospital - Comparison with Seasonal Influenza. Infection and Chemotherapy 43:5, 390
CrossRef195
Eun Young Choi, Jin Won Huh, Chae-Man Lim, Younsuck Koh, Sung-Han Kim, Sang-Ho Choi, Won Young Kim, Won Kim, Mi-Na Kim, Sang-Bum Hong. (2011) Critically Ill Patients with Pandemic Influenza A/H1N1 2009 at a Medical Center in Korea. Tuberculosis and Respiratory Diseases 70:1, 28
CrossRef196
Y. DENG, X. H. PANG, P. YANG, W. X. SHI, L. L. TIAN, B. W. LIU, S. LI, S. J. CUI, Y. LI, G. L. LU, L. ZHANG, X. ZHANG, B. LIU, H. SEALE, F. HUANG, Q. Y. WANG. (2011) Serological survey of 2009 H1N1 influenza in residents of Beijing, China. Epidemiology and Infection 139:01, 52-58
CrossRef197
Min Jung Kwon, Chang Kyu Lee, Kyoung Ho Roh, Myung Hyun Nam, Soo Young Yoon, Chae Seung Lim, Yun Jung Cho, Young Kee Kim, Kap No Lee. (2011) Clinical Characteristics and Comparison of the Various Methods Used for the Diagnosis of the New Influenza A Pandemic in Korea. Laboratory Medicine Online 1:1, 26
CrossRef198
Dragan Mikic, Darko Nozic, Miroslav Kojic, Svetlana Popovic, Dejan Hristovic, Radmila Rajic-Dimitrijevic, Petar Curcic, Milomir Milanovic, Rade Glavatovic, Vesna Begovic-Kupresanin, Milic Veljovic, Dragan Djordjevic, Nada Kuljic-Kapulica, Radovan Cekanac, Dara Stefanovic. (2011) Clinical manifestations, therapy and outcome of pandemic influenza a (H1N1) 2009 in hospitalized patients. Vojnosanitetski pregled 68:3, 248-256
CrossRef199
Ciro Esposito, Antimo Di Spirito, Nunzia Cuomo, Giuseppe Di Nicuolo, Giovanni Flaminio, Fabiana Altamura, Daniele Ambrosino, Federich Cantalupo, Caterina Costa, Francesca Pentimalli, Giulio Tarro. (2011) Tracking the 2009 H1N1 influenza virus in the Italian region Campania. Journal of Cellular Physiologyn/a-n/a
CrossRef200
J.A. Stockman. (2011) Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus. Yearbook of Pediatrics 2011, 268-270
CrossRef201
S. Buda, K. Köpke, W. Haas. (2010) Epidemiologischer Steckbrief der pandemischen Influenza (H1N1) 2009 basierend auf Einzelfallmeldungen nach Infektionsschutzgesetz. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 53:12, 1223-1230
CrossRef202
Xiaofan Ding, Lifang Jiang, Changwen Ke, Zhan Yang, Chunliang Lei, Kaiyuan Cao, Jun Xu, Lin Xu, Xingfen Yang, Yonghui Zhang, Ping Huang, Weijun Huang, Xun Zhu, Zhenjian He, Liping Liu, Jun Li, Jie Yuan, Jueheng Wu, Xiaoping Tang, Mengfeng Li. (2010) Amino acid sequence analysis and identification of mutations under positive selection in hemagglutinin of 2009 influenza A (H1N1) isolates. Virus Genes 41:3, 329-340
CrossRef203
Jin Leng, Daniel R. Goldstein. (2010) Impact of aging on viral infections. Microbes and Infection 12:14-15, 1120-1124
CrossRef204
Yuan Liu, Xiaoqing Liu, Jing Fang, Xiaona Shen, Wei Chen, Xiaojing Lin, Huaifang Li, Wenjie Tan, Yue Wang, Ping Zhao, Zhongtian Qi. (2010) Characterization of antibodies specific for hemagglutinin and neuraminidase proteins of the 1918 and 2009 pandemic H1N1 viruses. Vaccine 29:2, 183-190
CrossRef205
Ji-Young Min, Grace L Chen, Celia Santos, Elaine W Lamirande, Yumiko Matsuoka, Kanta Subbarao. (2010) Classical swine H1N1 influenza viruses confer cross protection from swine-origin 2009 pandemic H1N1 influenza virus infection in mice and ferrets. Virology 408:1, 128-133
CrossRef206
Woolf T Walker, Saul N Faust. (2010) Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Review of Vaccines 9:12, 1385-1398
CrossRef207
Abdullah S. Madhun, Per Espen Akselsen, Haakon Sjursen, Gabriel Pedersen, Signe Svindland, Jane Kristin Nøstbakken, Mona Nilsen, Kristin Mohn, Åsne Jul-Larsen, Ingrid Smith, Diane Major, John Wood, Rebecca J. Cox. (2010) An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 29:2, 266-273
CrossRef208
Ramu A. Subbramanian, Saleem Basha, Mohamed T. Shata, Rebecca C. Brady, David I. Bernstein. (2010) Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. Vaccine 28:52, 8258-8267
CrossRef209
Susanna Esposito, Emanuela D’Angelo, Cristina Daleno, Francesco Peia, Alessia Scala, Domenico Serra, Nadia Mirra, Carlotta Galeone, Nicola Principi. (2010) Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major. Vaccine 28:50, 7825-7828
CrossRef210
Gannon C. Mak, Perrin W.W. Choy, W.Y. Lee, Ann H. Wong, K.C. Ng, Wilina Lim. (2010) Sero-immunity and serologic response to pandemic influenza A (H1N1) 2009 virus in Hong Kong. Journal of Medical Virology 82:11, 1809-1815
CrossRef211
Suzanne L Epstein, Graeme E Price. (2010) Cross-protective immunity to influenza A viruses. Expert Review of Vaccines 9:11, 1325-1341
CrossRef212
Joan Puig-Barberà, Alberto Arnedo-Pena, Francisco Pardo-Serrano, María Dolores Tirado-Balaguer, Silvia Pérez-Vilar, Ester Silvestre-Silvestre, Consuelo Calvo-Mas, Lourdes Safont-Adsuara, Montserrat Ruiz-García. (2010) Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellón, Spain. A test-negative, hospital-based, case–control study. Vaccine 28:47, 7460-7467
CrossRef213
A. L. GREER, A. TUITE, D. N. FISMAN. (2010) Age, influenza pandemics and disease dynamics. Epidemiology and Infection 138:11, 1542-1549
CrossRef214
Julian W. Tang, Florence Y.L. Lai, P. Nymadawa, Yi-Mo Deng, Mala Ratnamohan, Martin Petric, Tze Ping Loh, Nancy W.S. Tee, Dominic E. Dwyer, Ian G. Barr, Felix Y.W. Wong. (2010) Comparison of the incidence of influenza in relation to climate factors during 2000-2007 in five countries. Journal of Medical Virology 82:11, 1958-1965
CrossRef215
Benjamin J. Cowling, Max S. Y. Lau, Lai-Ming Ho, Shuk-Kwan Chuang, Thomas Tsang, Shao-Haei Liu, Pak-Yin Leung, Su-Vui Lo, Eric H. Y. Lau. (2010) The Effective Reproduction Number of Pandemic Influenza. Epidemiology 21:6, 842-846
CrossRef216
Bin Zhou, Yan Li, Jessica A. Belser, Melissa B. Pearce, Mirco Schmolke, Anju X. Subba, Zhengli Shi, Sherif R. Zaki, Dianna M. Blau, Adolfo García-Sastre, Terrence M. Tumpey, David E. Wentworth. (2010) NS-based live attenuated H1N1 pandemic vaccines protect mice and ferrets. Vaccine 28:50, 8015-8025
CrossRef217
Li-Juan Liu, Xiao-Ai Zhang, Mao-Ti Wei, Cui He, Lei Zhang, Hong Yang, Wei Liu, Wu-Chun Cao, Dong-Sheng Xin, Ping-Yu Zhao, Cui He, Lei Zhang. (2010) The role of seasonal influenza vaccination in preventing pandemic 2009 influenza (H1N1) during a school outbreak. Journal of Clinical Virology 49:3, 225-226
CrossRef218
Hana Hakim, Jerry L Shenep. (2010) Managing fungal and viral infections in pediatric leukemia. Expert Review of Hematology 3:5, 603-624
CrossRef219
Hsiang-Chi Kung, Kuo-Chin Huang, Tsui-Mai Kao, Yi-Chien Lee, Feng-Yee Chang, Ning-Chi Wang, Yung-Ching Liu, Wen-Sen Lee, Hsing-Jin Liu, Chin-I Chen, Chien-Hui Chen, Li-Min Huang, Szu-Min Hsieh. (2010) A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. Vaccine 28:45, 7337-7343
CrossRef220
Ramu A. Subbramanian, Saleem Basha, Rebecca C. Brady, Staci Hazenfeld, Mohamed T. Shata, David I. Bernstein. (2010) Age-related changes in magnitude and diversity of cross-reactive CD4+ T-cell responses to the novel pandemic H1N1 influenza hemagglutinin. Human Immunology 71:10, 957-963
CrossRef221
Christopher Sikora, Shihe Fan, Richard Golonka, Doris Sturtevant, Jennifer Gratrix, Bonita E. Lee, Joy Jaipaul, Marcia Johnson. (2010) Transmission of pandemic influenza A (H1N1) 2009 within households: Edmonton, Canada. Journal of Clinical Virology 49:2, 90-93
CrossRef222
Matthew J. Memoli. (2010) pH1N1 influenza A: Timing is everything*. Critical Care Medicine 38:10, 2081-2082
CrossRef223
Vernon J. Lee, Joshua K. Tay, Mark I.C. Chen, M.C. Phoon, M.L. Xie, Y. Wu, Cynthia X.X. Lee, Jonathan Yap, K.R. Sakharkar, M.K. Sakharkar, Raymond T. Lin, Lin Cui, Paul M. Kelly, Yee Sin Leo, Yee Joo Tan, Vincent T.K. Chow. (2010) Inactivated trivalent seasonal influenza vaccine induces limited cross-reactive neutralizing antibody responses against 2009 pandemic and 1934 PR8 H1N1 strains. Vaccine 28:42, 6852-6857
CrossRef224
Donghyok Kwon, Kyeongcheol Shin, Seungtae Kim, Yooncheol Ha, Jang-Hoon Choi, Jeong Seon Yang, Joo-Yeon Lee, Chanhee Chae, Hee-Bok Oh, Chun Kang. (2010) Replication and pathogenesis of the pandemic (H1N1) 2009 influenza virus in mammalian models. The Journal of Microbiology 48:5, 657-662
CrossRef225
Julian W. Tang, Nandini Shetty, Tommy T.Y. Lam, K.L. Ellis Hon. (2010) Emerging, Novel, and Known Influenza Virus Infections in Humans. Infectious Disease Clinics of North America 24:3, 603-617
CrossRef226
Monica M. Farley. (2010) 2009 H1N1 Influenza: A Twenty-First Century Pandemic With Roots in the Early Twentieth Century. The American Journal of the Medical Sciences 340:3, 202-208
CrossRef227
Venkata R. S. K. Duvvuri, Seyed M. Moghadas, Hongbin Guo, Bhargavi Duvvuri, Jane M. Heffernan, David N. Fisman, Gillian E. Wu, Jianhong Wu. (2010) Original Article: Highly conserved cross-reactive CD4+ T-cell HA-epitopes of seasonal and the 2009 pandemic influenza viruses. Influenza and Other Respiratory Viruses 4:5, 249-258
CrossRef228
P J M Openshaw, J Dunning. (2010) Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak. Mucosal Immunology 3:5, 422-424
CrossRef229
Yuki Furuse, Kozue Shimabukuro, Takashi Odagiri, Rumi Sawayama, Takashi Okada, Irona Khandaker, Akira Suzuki, Hitoshi Oshitani. (2010) Comparison of selection pressures on the HA gene of pandemic (2009) and seasonal human and swine influenza A H1 subtype viruses. Virology 405:2, 314-321
CrossRef230
P. D. Griffiths. (2010) Back to the future with influenza. Reviews in Medical Virology 20:5, 263-264
CrossRef231
Tsui Mai Kao, Szu Min Hsieh, Hsiang Chi Kung, Yi Chien Lee, Kuo Chin Huang, Li Min Huang, Feng Yee Chang, Ning Chi Wang, Yung Ching Liu, Wen Sen Lee, Hsingjin Eugene Liu, Chin I. Chen, Chien-Hui Chen. (2010) Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. Vaccine 28:38, 6159-6163
CrossRef232
José María Navarro-Marí, José María Mayoral-Cortés, Mercedes Pérez-Ruiz, Jesús Rodríguez-Baño, Jordi Carratalá, Virtudes Gallardo-García. (2010) Infección en humanos por virus de la gripe A(H1N1): revisión al 30 de octubre de 2009. Enfermedades Infecciosas y Microbiología Clínica 28:7, 446-452
CrossRef233
Chi-Eun Oh, Jina Lee, Jin-Han Kang, Young-Jin Hong, Yun-Kyung Kim, Hee-Jin Cheong, Young-Joo Ahn, Sang-Hoon Kim, Hoan-Jong Lee. (2010) Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: A prospective, open-label, multi-center trial. Vaccine 28:36, 5857-5863
CrossRef234
Christine Korteweg, Jiang Gu. (2010) Pandemic influenza A (H1N1) virus infection and avian influenza A (H5N1) virus infection: a comparative analysisThis paper is one of a selection of papers published in this special issue entitled “Second International Symposium on Recent Advances in Basic, Clinical, and Social Medicine” and has undergone the Journal's usual peer review process.. Biochemistry and Cell Biology 88:4, 575-587
CrossRef235
Alfonso Carmona, Félix Omeñaca, Juan C. Tejedor, Jose M. Merino, Tejaswini Vaman, Ilse Dieussaert, Paul Gillard, Javier Arístegui. (2010) Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 28:36, 5837-5844
CrossRef236
Jin Soo Shin, Seon Do Hwang, Hyun Soo Kim, Sung Whan Cho, Sang Heui Seo. (2010) Protection of Ferrets from Infection by Swine-Origin 2009 A (H1N1) Influenza Virus by the Inactivated Vaccine. Viral Immunology 23:4, 395-402
CrossRef237
P.W. Orellano, J.I. Reynoso, O. Carlino, O. Uez. (2010) Protection of trivalent inactivated influenza vaccine against hospitalizations among pandemic influenza A (H1N1) cases in Argentina. Vaccine 28:32, 5288-5291
CrossRef238
Helena C. Maltezou. (2010) Novel (pandemic) influenza A H1N1 in healthcare facilities: Implications for prevention and control. Scandinavian Journal of Infectious Diseases 42:6-7, 412-420
CrossRef239
Peter Pushko, Thomas Kort, Margret Nathan, Melissa B. Pearce, Gale Smith, Terrence M. Tumpey. (2010) Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28:30, 4771-4776
CrossRef240
Cowling, Benjamin J., Chan, Kwok Hung, Fang, Vicky J., Lau, Lincoln L.H., So, Hau Chi, Fung, Rita O.P., Ma, Edward S.K., Kwong, Alfred S.K., Chan, Chi-Wai, Tsui, Wendy W.S., Ngai, Ho-Yin, Chu, Daniel W.S., Lee, Paco W.Y., Chiu, Ming-Chee, Leung, Gabriel M., Peiris, Joseph S.M., . (2010) Comparative Epidemiology of Pandemic and Seasonal Influenza A in Households. New England Journal of Medicine 362:23, 2175-2184
Full Text241
Kelvin Kai-Wang To, Iris Wai-Sum Li, Ivan Fan-Ngai Hung, Vincent Chi-Chung Cheng, Kwok-Yung Yuen. (2010) Pathogenesis of pandemic H1N1 2009 influenza virus infection and the implication on management. Frontiers of Medicine in China 4:2, 147-156
CrossRef242
Nathan Grills, Leonard S. Piers, Ian Barr, Loretta M. Vaughan, Rosemary Lester, Dianna J. Magliano, Jonathan E. Shaw, John A. Carnie. (2010) A lower than expected adult Victorian community attack rate for pandemic (H1N1) 2009. Australian and New Zealand Journal of Public Health 34:3, 228-231
CrossRef243
E. Busi Rizzi, V. Schininà, F. Ferraro, L. Rovighi, M. Cristoforo, D. Chiappetta, F. Lisena, F. Lauria, C. Bibbolino. (2010) Radiological findings of pneumonia in patients with swine-origin influenza A virus (H1N1). La radiologia medica 115:4, 507-515
CrossRef244
Julian W Tang, Nandini Shetty, Tommy Tsan-Yuk Lam. (2010) Features of the new pandemic influenza A/H1N1/2009 virus: virology, epidemiology, clinical and public health aspects. Current Opinion in Pulmonary Medicine 16:3, 235-241
CrossRef245
Regina Allwinn, Janina Geiler, Annemarie Berger, J. Cinatl, H. W. Doerr. (2010) Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans?. Medical Microbiology and Immunology 199:2, 117-121
CrossRef246
Amanda Beaudoin, Marie Gramer, Gregory C. Gray, Ana Capuano, Sharon Setterquist, Jeff Bender. (2010) Serologic survey of swine workers for exposure to H2N3 swine influenza A. Influenza and Other Respiratory Viruses 4:3, 163-170
CrossRef247
John C. Kash, Li Qi, Vivien G. Dugan, Brett W. Jagger, Rachel J. Hrabal, Matthew J. Memoli, David M. Morens, Jeffery K. Taubenberger. (2010) Prior infection with classical swine H1N1 influenza viruses is associated with protective immunity to the 2009 pandemic H1N1 virus. Influenza and Other Respiratory Viruses 4:3, 121-127
CrossRef248
R. Xu, D. C. Ekiert, J. C. Krause, R. Hai, J. E. Crowe, I. A. Wilson. (2010) Structural Basis of Preexisting Immunity to the 2009 H1N1 Pandemic Influenza Virus. Science 328:5976, 357-360
CrossRef249
Wei Lu, Paul A Tambyah. (2010) Safety and immunogenicity of influenza A H1N1 vaccines. Expert Review of Vaccines 9:4, 365-369
CrossRef250
Wook Jin Choi, Won Young Kim, Sung-Han Kim, Bum Jin Oh, Won Kim, Kyung Su Lim, Sang-Bum Hong, Chae-Man Lim, Yoinsuck Koh. (2010) Clinical characteristics of pneumonia in hospitalized patients with novel influenza A (H1N1) in Korea. Scandinavian Journal of Infectious Diseases 42:4, 311-314
CrossRef251
Michael B. Rothberg, Sarah D. Haessler. (2010) Complications of seasonal and pandemic influenza. Critical Care Medicine 38, e91-e97
CrossRef252
David M. Morens, Jeffery K. Taubenberger, Hillery A. Harvey, Matthew J. Memoli. (2010) The 1918 influenza pandemic: Lessons for 2009 and the future. Critical Care Medicine 38, e10-e20
CrossRef253
Michael C.W. Chan, Renee W.Y. Chan, Wendy C.L. Yu, Carol C.C. Ho, Kit M. Yuen, Joanne H.M. Fong, Lynsia L.S. Tang, Wico W. Lai, Amy C.Y. Lo, W.H. Chui, Alan D.L. Sihoe, Dora L.W. Kwong, David S.H. Wong, George S.W. Tsao, Leo L.M. Poon, Yi Guan, John M. Nicholls, Joseph S.M. Peiris. (2010) Tropism and Innate Host Responses of the 2009 Pandemic H1N1 Influenza Virus in ex Vivo and in Vitro Cultures of Human Conjunctiva and Respiratory Tract. The American Journal of Pathology 176:4, 1828-1840
CrossRef254
A. J. Valleron, B. Guidet. (2010) Real-time comparative monitoring of the A/H1N1 pandemic in France. Clinical Microbiology and Infection 16:4, 393-396
CrossRef255
Roberto Burioni, Filippo Canducci, Nicasio Mancini, Nicola Clementi, Monica Sassi, Donata De Marco, Roberta Antonia Diotti, Diego Saita, Michela Sampaolo, Giuseppe Sautto, Matteo Pianezze, Massimo Clementi. (2010) Monoclonal antibodies isolated from human B cells neutralize a broad range of H1 subtype influenza A viruses including swine-origin Influenza virus (S-OIV). Virology 399:1, 144-152
CrossRef256
Carrie Reed, Jacqueline M Katz. (2010) Serological surveys for 2009 pandemic influenza A H1N1. The Lancet 375:9720, 1062-1063
CrossRef257
R. Gasparini, F. Schioppa, M. Lattanzi, M. Barone, D. Casula, M. Pellegrini, K. Veitch, N. Gaitatzis. (2010) Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects. International Journal of Clinical Practice 64:4, 432-438
CrossRef258
Elizabeth Miller, Katja Hoschler, Pia Hardelid, Elaine Stanford, Nick Andrews, Maria Zambon. (2010) Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. The Lancet 375:9720, 1100-1108
CrossRef259
C. Casper, J. Englund, M. Boeckh. (2010) How I treat influenza in patients with hematologic malignancies. Blood 115:7, 1331-1342
CrossRef260
François Roman, Tejaswini Vaman, Beatrice Gerlach, Andre Markendorf, Paul Gillard, Jeanne-Marie Devaster. (2010) Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: Preliminary report of an observer-blind, randomised trial. Vaccine 28:7, 1740-1745
CrossRef261
Tao Jiang, XiaoPing Kang, Yongqiang Deng, Hui Zhao, Xiaofeng Li, Xuedong Yu, Man Yu, Ede Qin, Qingyu Zhu, Yinhui Yang, Chengfeng Qin. (2010) Development of a real-time RT-PCR assay for a novel influenza A (H1N1) virus. Journal of Virological Methods 163:2, 470-473
CrossRef262
G. D. Deans, H. G. Stiver, J. E. McElhaney. (2010) Influenza vaccines provide diminished protection but are cost-saving in older adults. Journal of Internal Medicine 267:2, 220-227
CrossRef263
Xiao-Feng Liang, Hua-Qing Wang, Jun-Zhi Wang, Han-Hua Fang, Jiang Wu, Feng-Cai Zhu, Rong-Cheng Li, Sheng-Li Xia, Yu-Liang Zhao, Fang-Jun Li, Shao-Hong Yan, Wei-Dong Yin, Kang An, Duo-Jia Feng, Xuan-Lin Cui, Feng-Chun Qi, Chang-Jun Ju, Yu-Hui Zhang, Zhi-Jun Guo, Ping-Yu Chen, Ze Chen, Kun-Ming Yan, Yu Wang. (2010) Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. The Lancet 375:9708, 56-66
CrossRef264
A. Pop-Vicas, S. Gravenstein. (2010) Influenza in the Elderly – A Mini-Review. Gerontology
CrossRef265
&NA;. (2010) Seasonal Trivalent Influenza Vaccine for 2009–2010. Obstetrics & Gynecology 115:1, 174-176
CrossRef266
Josep Vaqué. (2010) Epidemiología de la gripe A (H1N1) en el mundo y en España. Archivos de Bronconeumología 46, 3-12
CrossRef267
T. Jacob John, Mahesh Moorthy. (2010) 2009 Pandemic influenza in India. Indian Pediatrics 47:1, 25-31
CrossRef268
Jean Maritz, Leana Maree, Wolfgang Preiser. (2010) Pandemic influenza A (H1N1) 2009: the experience of the first six months. Clinical Chemistry and Laboratory Medicine 48:1, 11-21
CrossRef269
Eric Plennevaux, Eric Sheldon, Mark Blatter, Mary-Kate Reeves-Hoché, Martine Denis. (2010) Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. The Lancet 375:9708, 41-48
CrossRef270
Asawin Wanitchang, Jarin Kramyu, Anan Jongkaewwattana. (2010) Enhancement of reverse genetics-derived swine-origin H1N1 influenza virus seed vaccine growth by inclusion of indigenous polymerase PB1 protein. Virus Research 147:1, 145-148
CrossRef271
Grant W. WATERER, David S. HUI, Christine R. JENKINS. (2010) Public health management of pandemic (H1N1) 2009 infection in Australia: A failure!. Respirology 15:1, 51-56
CrossRef272
Heath Kelly, Ian Barr. (2010) Large trials confirm immunogenicity of H1N1 vaccines. The Lancet 375:9708, 6-9
CrossRef273
Sang In Park, Min Ji Kim, Ho Yeon Hwang, Chi Eun Oh, Jung Hyun Lee, Jae Sun Park. (2010) Clinical characteristics of children with 2009 pandemic influenza A (H1N1) admitted in a single institution. Korean Journal of Pediatrics 53:10, 886
CrossRef274
D. Kumar, M. I. Morris, C. N. Kotton, S. A. Fischer, M. G. Michaels, U. Allen, E. A. Blumberg, M. Green, A. Humar, M. G. Ison, . (2010) Guidance on Novel Influenza A/H1N1 in Solid Organ Transplant Recipients†. American Journal of Transplantation 10:1, 18-25
CrossRef275
A. Ho, R. Fox, R.A. Seaton, A. MacConnachie, E. Peters, C.L. Mackintosh, W.T.A. Todd, N. Kennedy, S. Dundas, R. Gunson. (2010) Hospitalised adult patients with Suspected 2009 H1N1 Infection at Regional Infectious Diseases Units in Scotland – Most had alternative final diagnoses. Journal of Infection 60:1, 83-85
CrossRef276
G. Del Giudice, K. J. Stittelaar, G. van Amerongen, J. Simon, A. D. M. E. Osterhaus, K. Stohr, R. Rappuoli. (2009) Seasonal Influenza Vaccine Provides Priming for A/H1N1 Immunization. Science Translational Medicine 1:12, 12re1-12re1
CrossRef277
Greenberg, Michael E., Lai, Michael H., Hartel, Gunter F., Wichems, Christine H., Gittleson, Charmaine, Bennet, Jillian, Dawson, Gail, Hu, Wilson, Leggio, Connie, Washington, Diane, Basser, Russell L., . (2009) Response to a Monovalent 2009 Influenza A (H1N1) Vaccine. New England Journal of Medicine 361:25, 2405-2413
Full Text278
Fisman, David N., , Savage, Rachel, Gubbay, Jonathan, Achonu, Camille, Akwar, Holy, Farrell, David J., Crowcroft, Natasha S., , Jackson, Phil, . (2009) Older Age and a Reduced Likelihood of 2009 H1N1 Virus Infection. New England Journal of Medicine 361:20, 2000-2001
Full Text279
Jain, Seema, Kamimoto, Laurie, Bramley, Anna M., Schmitz, Ann M., Benoit, Stephen R., Louie, Janice, Sugerman, David E., Druckenmiller, Jean K., Ritger, Kathleen A., Chugh, Rashmi, Jasuja, Supriya, Deutscher, Meredith, Chen, Sanny, Walker, John D., Duchin, Jeffrey S., Lett, Susan, Soliva, Susan, Wells, Eden V., Swerdlow, David, Uyeki, Timothy M., Fiore, Anthony E., Olsen, Sonja J., Fry, Alicia M., Bridges, Carolyn B., Finelli, Lyn, . (2009) Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009. New England Journal of Medicine 361:20, 1935-1944
Full Text280
ZA Memish, SJN McNabb, F Mahoney, F Alrabiah, N Marano, QA Ahmed, J Mahjour, RA Hajjeh, P Formenty, FH Harmanci, H El Bushra, TM Uyeki, M Nunn, N Isla, M Barbeschi. (2009) Establishment of public health security in Saudi Arabia for the 2009 Hajj in response to pandemic influenza A H1N1. The Lancet 374:9703, 1786-1791
CrossRef281
Mauricio Rodríguez-Álvarez, Ana María Velasco-Velasco, Nelson J. Álvarez-Anell, María Eugenia Jiménez-Corona, Samuel Ponce de León-Rosales. (2009) Identification of Seasonal Vaccine Hemagglutinin Subtype 1 (H1) Epitopes in Mexican Isolates of the New Influenza A (H1N1) 2009 Virus. Archives of Medical Research 40:8, 687-692
CrossRef
